CN116514678A - Novel coronavirus inhibitor, pharmaceutical composition containing same and use thereof - Google Patents
Novel coronavirus inhibitor, pharmaceutical composition containing same and use thereof Download PDFInfo
- Publication number
- CN116514678A CN116514678A CN202210072991.9A CN202210072991A CN116514678A CN 116514678 A CN116514678 A CN 116514678A CN 202210072991 A CN202210072991 A CN 202210072991A CN 116514678 A CN116514678 A CN 116514678A
- Authority
- CN
- China
- Prior art keywords
- straight
- branched
- chain
- phenyl
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000711573 Coronaviridae Species 0.000 title claims abstract description 20
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 14
- 239000003112 inhibitor Substances 0.000 title abstract description 11
- 201000010099 disease Diseases 0.000 claims abstract description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 23
- 208000025721 COVID-19 Diseases 0.000 claims abstract description 22
- 208000037847 SARS-CoV-2-infection Diseases 0.000 claims abstract description 21
- 206010035664 Pneumonia Diseases 0.000 claims abstract description 8
- 150000001875 compounds Chemical class 0.000 claims description 190
- -1 hydroxy, amino Chemical group 0.000 claims description 57
- 125000001997 phenyl group Chemical class [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 50
- 229910052736 halogen Inorganic materials 0.000 claims description 35
- 150000002367 halogens Chemical class 0.000 claims description 34
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 34
- 125000000217 alkyl group Chemical group 0.000 claims description 31
- 125000003342 alkenyl group Chemical group 0.000 claims description 28
- 125000000304 alkynyl group Chemical group 0.000 claims description 28
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 28
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 24
- 125000002947 alkylene group Chemical group 0.000 claims description 22
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 22
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 19
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 19
- 150000003839 salts Chemical class 0.000 claims description 19
- 125000005842 heteroatom Chemical group 0.000 claims description 16
- 229910052760 oxygen Inorganic materials 0.000 claims description 16
- 125000003545 alkoxy group Chemical group 0.000 claims description 15
- 125000004419 alkynylene group Chemical group 0.000 claims description 15
- 125000001424 substituent group Chemical group 0.000 claims description 15
- 238000011282 treatment Methods 0.000 claims description 15
- 125000004450 alkenylene group Chemical group 0.000 claims description 14
- 229910052717 sulfur Inorganic materials 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 13
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 13
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 claims description 11
- 241000124008 Mammalia Species 0.000 claims description 10
- 125000003118 aryl group Chemical group 0.000 claims description 10
- 125000001153 fluoro group Chemical group F* 0.000 claims description 8
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 7
- 125000001624 naphthyl group Chemical group 0.000 claims description 7
- 125000006584 (C3-C10) heterocycloalkyl group Chemical group 0.000 claims description 6
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 claims description 6
- 125000002541 furyl group Chemical group 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 125000001041 indolyl group Chemical group 0.000 claims description 6
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 6
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 6
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 6
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 6
- 125000004076 pyridyl group Chemical group 0.000 claims description 6
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 6
- 125000001544 thienyl group Chemical group 0.000 claims description 6
- 101710085938 Matrix protein Proteins 0.000 claims description 5
- 101710127721 Membrane protein Proteins 0.000 claims description 5
- 125000001072 heteroaryl group Chemical group 0.000 claims description 5
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 5
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 5
- 229920002554 vinyl polymer Polymers 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 4
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 3
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 claims description 3
- 229960004150 aciclovir Drugs 0.000 claims description 3
- 239000003242 anti bacterial agent Substances 0.000 claims description 3
- 230000002924 anti-infective effect Effects 0.000 claims description 3
- 229940088710 antibiotic agent Drugs 0.000 claims description 3
- 229960005475 antiinfective agent Drugs 0.000 claims description 3
- 239000003443 antiviral agent Substances 0.000 claims description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 3
- 108010086003 delta interferon Proteins 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 229910052731 fluorine Inorganic materials 0.000 claims description 3
- 239000011737 fluorine Substances 0.000 claims description 3
- 125000005843 halogen group Chemical group 0.000 claims description 3
- 239000002955 immunomodulating agent Substances 0.000 claims description 3
- 229940121354 immunomodulator Drugs 0.000 claims description 3
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 3
- 238000011321 prophylaxis Methods 0.000 claims description 3
- 229940121649 protein inhibitor Drugs 0.000 claims description 3
- 239000012268 protein inhibitor Substances 0.000 claims description 3
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 3
- 125000004429 atom Chemical group 0.000 claims description 2
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 claims description 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims description 2
- 229960001997 adefovir Drugs 0.000 claims 2
- WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 claims 2
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 8
- 230000003013 cytotoxicity Effects 0.000 abstract description 7
- 231100000135 cytotoxicity Toxicity 0.000 abstract description 7
- 230000002401 inhibitory effect Effects 0.000 abstract description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 149
- 238000002360 preparation method Methods 0.000 description 145
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 54
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 30
- 238000006243 chemical reaction Methods 0.000 description 24
- 239000000243 solution Substances 0.000 description 23
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 20
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 16
- 125000004432 carbon atom Chemical group C* 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 15
- 239000012043 crude product Substances 0.000 description 14
- 241001678559 COVID-19 virus Species 0.000 description 13
- 241000700605 Viruses Species 0.000 description 13
- 239000000203 mixture Substances 0.000 description 13
- 239000007787 solid Substances 0.000 description 13
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 239000007788 liquid Substances 0.000 description 12
- 230000000875 corresponding effect Effects 0.000 description 11
- 239000012074 organic phase Substances 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 239000005457 ice water Substances 0.000 description 9
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 238000003818 flash chromatography Methods 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 8
- 239000000969 carrier Substances 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 229940125782 compound 2 Drugs 0.000 description 6
- 229940126214 compound 3 Drugs 0.000 description 6
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 229940125904 compound 1 Drugs 0.000 description 5
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 5
- 108010026228 mRNA guanylyltransferase Proteins 0.000 description 5
- 210000004779 membrane envelope Anatomy 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- 101710139375 Corneodesmosin Proteins 0.000 description 4
- 102100031673 Corneodesmosin Human genes 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 108700026244 Open Reading Frames Proteins 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- VSTXCZGEEVFJES-UHFFFAOYSA-N 1-cycloundecyl-1,5-diazacycloundec-5-ene Chemical compound C1CCCCCC(CCCC1)N1CCCCCC=NCCC1 VSTXCZGEEVFJES-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 3
- 150000001299 aldehydes Chemical class 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 description 2
- PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 2
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 2
- 108020005345 3' Untranslated Regions Proteins 0.000 description 2
- 108020003589 5' Untranslated Regions Proteins 0.000 description 2
- 108020005544 Antisense RNA Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 238000006646 Dess-Martin oxidation reaction Methods 0.000 description 2
- 101710204837 Envelope small membrane protein Proteins 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- 206010025327 Lymphopenia Diseases 0.000 description 2
- 101710145006 Lysis protein Proteins 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 101710172711 Structural protein Proteins 0.000 description 2
- 108091027544 Subgenomic mRNA Proteins 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 108020000999 Viral RNA Proteins 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 239000003184 complementary RNA Substances 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 239000006184 cosolvent Substances 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 241001493065 dsRNA viruses Species 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 2
- 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 231100001023 lymphopenia Toxicity 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000002390 rotary evaporation Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 2
- 235000019345 sodium thiosulphate Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- 239000012224 working solution Substances 0.000 description 2
- LLJFNWVJKMVHIL-UHFFFAOYSA-N (2-methoxy-2-oxoethyl)phosphonic acid Chemical compound COC(=O)CP(O)(O)=O LLJFNWVJKMVHIL-UHFFFAOYSA-N 0.000 description 1
- AFDXODALSZRGIH-QPJJXVBHSA-N (E)-3-(4-methoxyphenyl)prop-2-enoic acid Chemical compound COC1=CC=C(\C=C\C(O)=O)C=C1 AFDXODALSZRGIH-QPJJXVBHSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- FYADHXFMURLYQI-UHFFFAOYSA-N 1,2,4-triazine Chemical compound C1=CN=NC=N1 FYADHXFMURLYQI-UHFFFAOYSA-N 0.000 description 1
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 1
- VXNZUUAINFGPBY-UHFFFAOYSA-N 1-Butene Chemical group CCC=C VXNZUUAINFGPBY-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 description 1
- YPLIJSBLBJHNKT-UHFFFAOYSA-N 2-(cyclohexen-1-yl)oxane Chemical compound O1CCCCC1C1=CCCCC1 YPLIJSBLBJHNKT-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- KWMBADTWRIGGGG-UHFFFAOYSA-N 2-diethoxyphosphorylacetonitrile Chemical compound CCOP(=O)(CC#N)OCC KWMBADTWRIGGGG-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 101800000535 3C-like proteinase Proteins 0.000 description 1
- 101800002396 3C-like proteinase nsp5 Proteins 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- CSDQQAQKBAQLLE-UHFFFAOYSA-N 4-(4-chlorophenyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine Chemical compound C1=CC(Cl)=CC=C1C1C(C=CS2)=C2CCN1 CSDQQAQKBAQLLE-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102000053723 Angiotensin-converting enzyme 2 Human genes 0.000 description 1
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 description 1
- 235000003911 Arachis Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010050685 Cytokine storm Diseases 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 101000638154 Homo sapiens Transmembrane protease serine 2 Proteins 0.000 description 1
- 244000309467 Human Coronavirus Species 0.000 description 1
- 241000711467 Human coronavirus 229E Species 0.000 description 1
- 241001109669 Human coronavirus HKU1 Species 0.000 description 1
- 241000482741 Human coronavirus NL63 Species 0.000 description 1
- 241001428935 Human coronavirus OC43 Species 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 208000034486 Multi-organ failure Diseases 0.000 description 1
- 208000010718 Multiple Organ Failure Diseases 0.000 description 1
- MDXGYYOJGPFFJL-QMMMGPOBSA-N N(alpha)-t-butoxycarbonyl-L-leucine Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)OC(C)(C)C MDXGYYOJGPFFJL-QMMMGPOBSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 101150001779 ORF1a gene Proteins 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 101800004803 Papain-like protease Proteins 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229940096437 Protein S Drugs 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 101710153041 Replicase polyprotein 1a Proteins 0.000 description 1
- 101710151619 Replicase polyprotein 1ab Proteins 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 241000315672 SARS coronavirus Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 101710198474 Spike protein Proteins 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- IYABWNGZIDDRAK-UHFFFAOYSA-N allene Chemical group C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 206010052015 cytokine release syndrome Diseases 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000005560 droplet transmission Effects 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- 125000005677 ethinylene group Chemical group [*:2]C#C[*:1] 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000028023 exocytosis Effects 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 210000002288 golgi apparatus Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- FRIJBUGBVQZNTB-UHFFFAOYSA-M magnesium;ethane;bromide Chemical compound [Mg+2].[Br-].[CH2-]C FRIJBUGBVQZNTB-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- YZMHQCWXYHARLS-UHFFFAOYSA-N naphthalene-1,2-disulfonic acid Chemical compound C1=CC=CC2=C(S(O)(=O)=O)C(S(=O)(=O)O)=CC=C21 YZMHQCWXYHARLS-UHFFFAOYSA-N 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- AFDXODALSZRGIH-UHFFFAOYSA-N p-coumaric acid methyl ether Natural products COC1=CC=C(C=CC(O)=O)C=C1 AFDXODALSZRGIH-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960005190 phenylalanine Drugs 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229940068886 polyethylene glycol 300 Drugs 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000006410 propenylene group Chemical group 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- MWWATHDPGQKSAR-UHFFFAOYSA-N propyne Chemical group CC#C MWWATHDPGQKSAR-UHFFFAOYSA-N 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 1
- JUJBNYBVVQSIOU-UHFFFAOYSA-M sodium;4-[2-(4-iodophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].C1=CC([N+](=O)[O-])=CC=C1N1[N+](C=2C=CC(I)=CC=2)=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=N1 JUJBNYBVVQSIOU-UHFFFAOYSA-M 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 230000010472 type I IFN response Effects 0.000 description 1
- 229940005605 valeric acid Drugs 0.000 description 1
- 230000007502 viral entry Effects 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to novel coronavirus inhibitors, pharmaceutical compositions containing them and their use. The inhibitor of the invention has better activity of inhibiting novel coronaviruses and lower cytotoxicity, namely higher safety, and can be used for preventing and/or treating diseases caused by SARS-CoV-2 infection, such as novel coronavirus pneumonia.
Description
Technical Field
The present invention relates to compounds for the treatment of novel coronavirus (SARS-CoV-2) infection, pharmaceutical compositions containing the same and uses thereof.
Background
The novel coronavirus pneumonia (COVID-19) is caused by a novel coronavirus (SARS-CoV-2) infection. The novel coronavirus has the advantages of high transmission speed, wide infection range and high prevention and control difficulty. The novel coronavirus transmission modes include droplet transmission and aerosol transmission. The clinical symptoms after infection are commonly shown as fever, dry cough, laryngalgia, dyspnea, nausea, vomiting and the like, and severe patients are accompanied with acute respiratory distress syndrome, septicemia, multiple organ failure and the like. Diagnostically, it was found that mild patients had lymphopenia, leukopenia, increased CRP, severe patients had increased transaminase, lactate dehydrogenase, and the like.
Based on phylogenetic and taxonomical considerations and established conventions, the International Commission on viral classification classifies SARS-CoV-2 as belonging to the genus Coronaviridae of the order nidoviridae. The coronaviruses found to infect humans are HCoV-229E, HCoV-NL63 of the alpha genus and HCoV-HKU1, HCoV-OC43, MERS-CoV, SARA-CoV and SARS-CoV-2 of the beta genus. In addition to SARS-CoV, MERS-CoV and SARS-CoV-2 being highly pathogenic viruses, other human coronaviruses are likely to spread in humans for a long period of time, but typically cause only relatively mild respiratory disease.
SARS-CoV-2 is a single-stranded positive sense RNA virus, having a genome of about 30kbp, with the largest genome in RNA viruses. SARS-CoV-2 is spherical or elliptic and has a diameter of 80-120nm. The surface of the virus under the electron microscope is provided with a rod-shaped protruding part which consists of a trimer spike protein (S) and is divided into a large extracellular domain and a small intracellular domain; the viral envelope is composed of a membrane protein (M) containing three transmembrane structures, wherein some transmembrane envelope proteins (E) are inserted, and the genome RNA is wrapped by a nucleocapsid protein (N) to form a spiral shape and further surrounded by the envelope. The genome is, in order from the 5 'end to the 3' end: 5 'cap structure-leader-UTR-replicase-S-E-M-N-URT-3' polyA. The methylated cap structure and Poly A at both ends allow it to be used as mRNA for direct protein translation of the replicase domain. There are at least 11 open reading frames (Open reading frame, ORFs) on the genome, where the upstream ORF1a and ORF1b contain the replicase domain genes, approximately 20kbp, accounting for 66% of the entire genome, encoding the nonstructural proteins, and downstream is the genome encoding the structural and accessory proteins, approximately 10kbp, interspersed with the structural protein genome. The open reading frame is flanked by untranslated regions 5'UTR and 3' UTR, the 5'UTR being an important structure for genome replication and transcription, the 3' UTR being capable of regulating genome replication and transcription, and the replicase domain gene comprising a leader sequence upstream.
The process of infecting host cells with SARS-CoV-2 is divided into five steps: viral entry, expression of replicase genes, replication transcription and translation of the genome, assembly and release of progeny viruses. The host cells are mainly type II lung epithelial cells. The pathway into the target cell is the specific binding of the S protein to ACE2 receptor on the host cell surface, inducing the protease TMPRSS2 to hydrolyze the S protein, the S protein being activated, the viral envelope fusing with the cytoplasmic membrane, the rapid entry into the host cell by endocytosis of the lipid envelope, vesicle and viral particle fusion, and release of the viral genome into the cytoplasm. After the virus enters the host cell, endolysosomal digestion of viral nucleocapsid proteins is initiated, viral RNA is released, viral genomic RNA can be used as mRNA, translated and frameshifted to produce precursor multimeric proteins pp1a and pp1ab, which are further hydrolyzed by the main protease and papain-like protease to nonstructural proteins required for replication and transcription of the virus. Under the action of virus replicase, the virus genome RNA takes itself as template to synthesize full-length antisense RNA, and the antisense RNA takes itself as template to synthesize new genome RNA. The polymerase can switch templates in the discontinuous transcription process of specific sites of genomic RNA to generate 5 '-nested antisense sgRNA, and the 5' -nested antisense sgRNA is synthesized by taking the template as the template, so that structural proteins and auxiliary proteins are translated, S proteins, E proteins and M proteins are transferred from an endoplasmic reticulum to an endoplasmic reticulum golgi intermediate complex, N proteins form a nucleocapsid to wrap progeny viral RNA, E proteins promote M proteins to form a viral envelope on ERGIC, the viral envelope is assembled into a mature virion, transported to a cytoplasmic membrane through a golgi apparatus and a secretion vesicle, and released outside a host cell by exocytosis.
The immune response occurs mainly in capillaries. On the innate immune level, type i interferon responses are delayed or inhibited during initial infection, viral replication triggers a hyper-inflammatory response and cytokine storm, activated neutrophils and inflammatory mononucleated/macrophages are increased, serum neutrophils and elevated pro-inflammatory cytokines are correlated with the severity of the disease. In terms of adaptive immune responses, helper T cells Th1/Th17 are activated, igA, igM and IgG are usually detectable within two weeks of infection, and lymphopenia may be associated with myelosuppression.
Since the beginning of 2020, there has been a desire to find compounds that are effective in inhibiting novel coronaviruses.
Disclosure of Invention
The invention provides an effective inhibitor aiming at SARS-CoV-2 virus, and also provides a pharmaceutical composition containing the inhibitor and application thereof.
According to a first aspect of the present invention, the present invention relates to a compound of formula I:
wherein:
R 1 represents Z-Y-X-,
x represents a bond; alternatively, O;
y represents a bond; alternatively, C 1-10 Straight-chain or branched alkylene, C 2-10 Straight-chain or branched alkenylene or C 2-10 A linear or branched alkynylene group, the alkylene, alkenylene, or alkynylene group being unsubstituted or substituted with 1 or more halogens;
Z represents H; c (C) 3-10 Cycloalkyl or 3-10 membered heterocycloalkyl containing 1-3 heteroatoms independently selected from N, O, S, said cycloalkyl or heterocycloalkyl being unsubstituted or substituted with 1 or more substituents independently selected from halogen, C 1-10 Straight-chain or branched alkyl, C 2-10 Straight-chain or branched alkenyl, C 2-10 Straight or branched alkynyl, C 1-10 Linear or branched alkyl oxy, hydroxy, amino, cyano, nitro, trifluoromethyl, trifluoromethoxy groups; alternatively, C 6-10 Aryl or 5-10 membered heteroaryl containing 1-3 heteroatoms independently selected from N, O, S, said aryl or heteroaryl being unsubstituted or substituted with 1 or more substituents independently selected from halogen, C 1-10 Straight-chain or branched alkyl, C 2-10 Straight-chain or branched alkenyl, C 2-10 Straight or branched alkynyl, C 1-10 Straight or branched chain alkyl oxy, notSubstituted or by C 1-6 Alkyl-substituted phenyl, hydroxy, amino, cyano, nitro, trifluoromethyl, trifluoromethoxy groups;
provided that when Y is a bond, Z is not H;
R 2 represents phenyl, C 1-10 Straight-chain or branched alkylene phenyl, C 2-10 Straight-chain or branched alkenylene phenyl or C 2-10 Straight or branched alkynylene phenyl, said phenyl being unsubstituted or substituted with 1 or more groups independently selected from halogen, C 1-10 Straight-chain or branched alkyl, C 2-10 Straight-chain or branched alkenyl, C 2-10 Straight or branched alkynyl, C 1-10 Linear or branched alkyl oxy, hydroxy, amino, cyano, nitro, trifluoromethyl, trifluoromethoxy groups;
R 3 represents hydrogen; c (C) 1-10 Straight-chain or branched alkyl, C 2-10 Straight-chain or branched alkenyl or C 2-10 A linear or branched alkynyl group, said alkyl, alkenyl or alkynyl group being unsubstituted or substituted with 1 or more halogens; c (C) 3-10 Cycloalkyl, C 1-10 Straight-chain or branched alkylene C 3-10 Cycloalkyl, C 2-10 Straight-chain or branched alkenylene C 3-10 Cycloalkyl, C 2-10 Straight-chain or branched alkynylene C 3-10 Cycloalkyl, phenyl, C 1-10 Straight-chain or branched alkylene phenyl, C 2-10 Straight-chain or branched alkenylene phenyl or C 2-10 A straight or branched alkynylene phenyl group, said cycloalkyl or phenyl group being unsubstituted or substituted with 1 or more groups independently selected from halogen, C 1-10 Straight-chain or branched alkyl, C 2-10 Straight-chain or branched alkenyl, C 2-10 Straight or branched alkynyl, C 1-10 Linear or branched alkyl oxy, hydroxy, amino, cyano, nitro, trifluoromethyl, trifluoromethoxy groups;
R 4 represents-CHO.
In a preferred embodiment, in the compounds of formula I:
R 1 represents Z-Y-X-,
x represents a bond; alternatively, O;
y represents a bond; alternatively, C 1-6 Straight-chain or branched alkylene, C 2-6 Straight-chain or branched alkenylene, or C 2-6 A linear or branched alkynylene group, said alkylene, alkenylene, or alkynylene group being unsubstituted or substituted with 1-3 fluorine groups;
z represents H; c (C) 3-10 Cycloalkyl or 3-10 membered heterocycloalkyl containing 1 heteroatom selected from N, O, S, said cycloalkyl or heterocycloalkyl being unsubstituted or substituted with 1-3 groups independently selected from halogen, C 1-6 Straight-chain or branched alkyl, C 2-6 Straight-chain or branched alkenyl, C 2-6 Straight or branched alkynyl, C 1-6 Linear or branched alkyl oxy, hydroxy, amino, cyano, nitro, trifluoromethyl, trifluoromethoxy groups; alternatively, C 6-10 Aryl or 5-10 membered heteroaryl containing 1-3 heteroatoms independently selected from N, O, S, said aryl or heteroaryl being unsubstituted or substituted with 1-3 heteroatoms independently selected from halogen, C 1-6 Straight-chain or branched alkyl, C 2-6 Straight-chain or branched alkenyl, C 2-6 Straight or branched alkynyl, C 1-6 Linear or branched alkyl oxygen, phenyl, hydroxy, amino, cyano, nitro, trifluoromethyl groups;
provided that when Y is a bond, Z is not H;
R 2 represents phenyl, C 1-6 Straight-chain or branched alkylene phenyl, C 2-6 Straight-chain or branched alkenylene phenyl or C 2-6 Straight or branched alkynylene phenyl groups, said phenyl groups being unsubstituted or substituted with 1 to 3 groups independently selected from halogen, C 1-6 Straight-chain or branched alkyl, C 2-6 Straight-chain or branched alkenyl, C 2-6 Straight or branched alkynyl, C 1-6 Linear or branched alkyl oxy, hydroxy, amino, cyano, nitro, trifluoromethyl, trifluoromethoxy groups;
R 3 represents hydrogen; methyl, n-propyl, C 4-6 Straight-chain or branched alkyl, C 4-6 Straight-chain or branched alkenyl or C 4-6 A linear or branched alkynyl group, said alkyl, alkenyl or alkynyl group being unsubstituted or substituted with 1 to 3 fluoro groups; c (C) 3-10 Cycloalkyl, C 1-6 Straight-chain or branched alkylene C 3-10 Cycloalkyl, C 2-6 Straight-chain or branched alkenylene C 3-10 Cycloalkyl, C 2-6 Straight-chain or branched alkynylene C 3-10 Cycloalkyl, phenyl, C 1-6 Straight-chain or branched alkylene phenyl, C 2-6 Straight-chain or branched alkenylene phenyl or C 2-6 Straight or branched alkynylene phenyl, said cycloalkyl or phenyl being unsubstituted or substituted with 1 to 3 groups independently selected from halogen, C 1-6 Straight-chain or branched alkyl, C 2-6 Straight-chain or branched alkenyl, C 2-6 Straight or branched alkynyl, C 1-6 Linear or branched alkyl oxy, hydroxy, amino, cyano, nitro, trifluoromethyl, trifluoromethoxy groups;
R 4 represents-CHO.
In a preferred embodiment, in the compounds of formula I:
R 1 represents Z-Y-X-,
x represents a bond; alternatively, O;
y represents a bond; or, C1-3 straight or branched alkylene, C2-3 straight or branched alkenylene;
Z represents H; a cyclohexenyl or 6 membered heterocycloalkyl containing 1 heteroatom selected from N, O, S, said cycloalkyl or heterocycloalkyl being unsubstituted or substituted with 1-3 groups independently selected from halo, methyl, methoxy, hydroxy, amino, cyano, nitro, trifluoromethyl, trifluoromethoxy; or, phenyl, naphthyl, pyrrolyl, furanyl, thienyl, indolyl, pyridinyl, isoxazolyl, pyrimidinyl, said substituents being unsubstituted or substituted with 1 to 3 groups independently selected from halogen, methyl, methoxy, phenyl, hydroxy, amino, cyano, nitro, trifluoromethyl, trifluoromethoxy;
provided that when Y is a bond, Z is not H;
R 2 represent C 1-3 A linear or branched alkylene phenyl group, said phenyl group being unsubstituted or substituted with 1 group selected from halogen, methyl, methoxy, hydroxy, amino, cyano, nitro, trifluoromethyl, trifluoromethoxy;
R 3 represents hydrogen; methyl, n-propyl, C 4-6 Linear or branched alkyl; c (C) 1-3 Linear or branched alkylene cyclohexanyl or C 1-3 A linear or branched alkylene phenyl group, said cyclohexyl or phenyl group being unsubstituted or substituted with 1 group selected from halogen, methyl, methoxy, hydroxy, amino, cyano, nitro, trifluoromethyl, trifluoromethoxy;
R 4 represents-CHO.
In a preferred embodiment, in the compounds of formula I:
R 1 represents Z-Y-X-,
x represents a bond; alternatively, O;
y represents a bond; alternatively, CH 2 、CH=CH;
Z represents a cyclohexenyl or a 6 membered heterocycloalkyl containing 1O atom, said cyclohexenyl or heterocycloalkyl being unsubstituted or substituted with 1 or 2 groups independently selected from halogen, methyl, methoxy, nitro; or, phenyl, naphthyl, pyrrolyl, furanyl, thienyl, indolyl, pyridyl, isoxazolyl, pyrimidinyl, said substituents being unsubstituted or substituted with 1 or 2 groups independently selected from halogen, methyl, vinyl, methoxy, phenyl, nitro;
R 2 represents a methylenephenyl or ethylenephenyl group, said phenyl group being unsubstituted or substituted in ortho, meta or para position with respect to the methylene or ethylene group by 1 group selected from halogen, methoxy, nitro, trifluoromethyl;
R 3 represents methyl, n-propyl, n-butyl, isobutyl, sec-butyl, tert-butyl; a methylenecyclohexenyl or methylenephenyl group, said cyclohexenyl or phenyl group being unsubstituted or substituted with 1 group selected from halogen in the ortho, meta or para position to the methylene group;
R 4 represents-CHO.
In a preferred embodiment, the compounds of formula I
R 1 Selected from the group consisting of pentyl, phenyl, ethenylene, methylenephenyl, -O-methylenephenyl, phenylenephenyl, naphthyl, pyrrolyl, furanyl, thienyl, indolyl, methyleneindolyl, pyridyl, isoxazolyl, cyclohexenyl,Tetrahydropyran, said substituents being unsubstituted or substituted with 1 or 2 groups independently selected from fluoro, chloro, bromo, methyl, vinyl, methoxy, nitro;
R 2 selected from the group consisting of methylenephenyl, said phenyl being unsubstituted or substituted with 1 group selected from fluoro, chloro, bromo, methoxy, nitro, trifluoromethyl, ortho, meta or para to the methylene;
R 3 selected from isobutyl; a methylenecyclohexenyl or methylenephenyl group, said cyclohexenyl or phenyl group being unsubstituted or substituted with 1 fluorine at the ortho, meta or para position relative to the methylene group;
R 4 represents-CHO.
In a preferred embodiment, the compound of formula I is selected from:
definition of terms in the present invention:
in the present invention, "halogen" means fluorine, chlorine, bromine, iodine;
in the present invention, "C 1-10 The straight-chain or branched alkyl group "means a straight-chain or branched alkyl group having 1 to 10 carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, n-hexyl, etc. This definition applies equally to the corresponding alkyl groups having fewer carbon atoms, e.g. C 1-6 Straight or branched alkyl groups, etc., and corresponding alkyl groups in other more complex substituents, e.g. C 1-10 Linear or branched alkyl oxy groups, and the like;
in the present invention, "C 2-10 Straight chain or linearBranched alkenyl "refers to straight or branched alkenyl groups having 2 to 10 carbon atoms, such as vinyl, allyl, propenyl, and the like. This definition applies equally to the corresponding alkenyl groups having fewer carbon atoms, e.g. C 2-6 Straight or branched alkenyl groups, and the like;
in the present invention, "C 2-10 Straight or branched alkynyl "refers to straight or branched alkynyl groups having 2 to 10 carbon atoms, such as ethynyl, propargyl, propynyl, and the like. This definition applies equally to the corresponding alkynyl groups having fewer carbon atoms, e.g. C 2-6 Straight or branched chain alkynyl groups, and the like;
in the present invention, "C 1-10 By straight or branched alkylene "is meant straight or branched alkylene having 1 to 10 carbon atoms, such as methylene, ethylene, n-propylene, isopropylene, n-butylene. This definition applies equally to the corresponding alkylene groups having fewer carbon atoms, e.g. C 1-6 Straight-chain or branched alkylene groups, etc., and corresponding alkylene groups in other more complex substituents, e.g. C 1-10 Straight-chain or branched-chain alkylene phenyl groups, and the like;
in the present invention, "C 2-10 By straight or branched alkenylene "is meant straight or branched alkenylene having 2 to 10 carbon atoms, such as ethenylene, allylene, propenylene, and the like. This definition applies equally to the corresponding alkenylene radicals having fewer carbon atoms, for example C 2-6 Straight-chain or branched alkenylene groups, etc., and corresponding alkenylene groups in other more complex substituents, e.g. C 2-10 Linear or branched alkenylene phenyl, and the like;
in the present invention, "C 2-10 Straight or branched alkynylene "refers to straight or branched alkynylene groups having 2 to 10 carbon atoms, such as ethynylene, propargyl, propynylene, and the like. This definition applies equally to the corresponding alkynylene radicals having fewer carbon atoms, e.g. C 2-6 Straight-chain or branched alkynylene radicals and the like, as well as corresponding alkynylene radicals suitable for use in other more complex substituents, e.g. C 2-10 Straight-chain or branched alkynylene phenyl groups and the like;
in the present invention, "C 3-10 Cycloalkyl "means cycloalkyl having 3 to 10 carbon atoms, including monocyclic orCondensed rings such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, adamantyl, and the like;
in the present invention, "3-10 membered heterocycloalkyl containing 1 to 3 heteroatoms independently selected from N, O, S" means a 3-10 membered heterocycloalkyl having 1 or 2 or 3 heteroatoms independently selected from N, O, S, including a single ring or a condensed ring, which is attached through one ring carbon atom or one ring nitrogen atom of the heterocycloalkyl group, such as tetrahydrofuranyl, pyrrolidinyl, tetrahydropyranyl, and the like;
In the present invention, "C 6-10 Aryl "refers to aryl groups having 6 to 10 carbon atoms and includes monocyclic or fused rings, such as phenyl, naphthyl, and the like.
In the present invention, "5-10 membered heteroaryl containing 1-3 heteroatoms independently selected from N, O, S" refers to a 5-10 membered heteroaryl having a single or fused ring, having 1 or 2 or 3 heteroatoms independently selected from N, O, S, which is attached through one ring carbon atom or one ring nitrogen atom of the heteroaryl, such as pyrrole, furan, thiophene, imidazole, pyrazole, thiazole, oxazole, isoxazole, 1,2, 3-triazole, 1, 2-thiadiazole, pyridine, pyrazine, pyrimidine, 1,2, 4-triazine, indole, benzoxazole, benzothiazole, quinoline, and the like;
in the present invention, "alkylene phenyl" means a phenyl group linked via an alkylene group. This definition applies equally to other analogous groups, for example C 1-10 Straight-chain or branched alkylene C 3-10 Cycloalkyl groups, and the like.
According to the present invention, a pharmaceutically acceptable salt means a pharmaceutically acceptable salt of a compound of formula I with an inorganic or organic acid. Inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid and the like, and organic acids such as formic acid, acetic acid, propionic acid, valeric acid, trifluoroacetic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, toluenesulfonic acid, naphthalenedisulfonic acid, malonic acid, maleic acid, succinic acid, fumaric acid, tartaric acid, malic acid, citric acid, gluconic acid, ascorbic acid, benzoic acid and the like.
The compound of the formula I or the pharmaceutically acceptable salt thereof can inhibit SARS-CoV-2, so that the compound can be used for preventing and/or treating diseases caused by SARS-CoV-2 infection, such as novel coronavirus pneumonia, and can be used alone or simultaneously with other compounds for treating diseases caused by SARS-CoV-2 infection.
According to a second aspect of the present invention, the present invention relates to a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
In a preferred embodiment, the pharmaceutical composition of the present invention further comprises other compounds for treating diseases caused by SARS-CoV-2 infection.
According to a third aspect of the present invention, the present invention relates to a method for the prophylaxis and/or treatment of a disease caused by SARS-CoV-2 infection in a mammal, by administering to the mammal a therapeutically effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to the present invention.
In a preferred embodiment, the prophylactic and/or therapeutic methods of the invention also administer to a mammal an additional compound for the treatment of a disease caused by SARS-CoV-2 infection. Other compounds for treating diseases caused by SARS-CoV-2 infection may be administered prior to, concurrently with, or subsequent to the administration of the compounds or compositions of the present invention.
According to a fourth aspect of the present invention, the present invention relates to the use of a compound of formula I or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the prevention and/or treatment of a disease caused by SARS-CoV-2 infection in a mammal.
According to a fifth aspect of the present invention, the present invention relates to the use of a compound of formula I or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the prevention and/or treatment of a disease caused by SARS-CoV-2 infection in a mammal in combination with other compounds for the treatment of a disease caused by SARS-CoV-2 infection.
In the present invention, preferably, the mammal is a human.
In the present invention, preferably, the disease caused by SARS-CoV-2 infection is a novel coronavirus pneumonia.
In the present invention, other compounds for treating diseases caused by SARS-CoV-2 infection are preferred, including but not limited to antiviral agents such as acyclovir, rituximab, monabivalvir and the like, antiinfectives, immunomodulators such as alpha, beta, delta-interferon and the like, primary protease inhibitors, S protease inhibitors, M protein inhibitors, and/or antibiotics and the like.
The pharmaceutical compositions of the present invention may be administered by a variety of routes known in the art including, but not limited to, oral, dermal, intradermal, subcutaneous, intramuscular, intraperitoneal, intravenous, pulmonary, epidural, intra-articular, intrasynovial, intrasternal, intrathecal, intralesional, ocular, oral, nasal, rectal, bronchial, and the like. Administration may also be through an implanted reservoir or through a drug-loaded stent. The administration may be systemic or local. Preferred routes of administration are oral, intravenous, nasal transmucosal administration, and bronchial sprays.
The pharmaceutical compositions of the present invention may be administered in a variety of pharmaceutical forms known in the art. The pharmaceutical carrier used may be solid or liquid.
The formulation using a solid carrier may be in the form of tablets (including but not limited to various coated tablets, slow-release or controlled-release tablets), powders or pellets placed into hard capsules, lozenges or troches, granules, dispersible powders, and the like. The amount of solid support varies to a large extent but is preferably from about 25mg to about 1.0g. Typical solid carriers include lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, stearic acid and the like. The solid carrier may comprise one or more substances which may act simultaneously as flavoring agents, lubricants, solubilizers, suspending agents, fillers, glidants, compression aids, binders or tablet-disintegrating agents; it may also be an encapsulating material. In powders, the carrier is a finely divided solid which is admixed with the finely divided active ingredient. The active ingredient is mixed in a suitable ratio in a tablet with a carrier having the necessary compression properties, compressed in the desired shape and size. The powders and tablets preferably contain up to 99% active ingredient.
Formulations using liquid carriers may be in the form of syrups, emulsions, soft capsules, sterile injectable solutions or suspensions in ampules or vials or non-aqueous liquid suspensions. Typical liquid carriers include syrup, peanut oil, olive oil, water, and the like. Liquid carriers are used in preparing solutions, suspensions, emulsions, syrups, tinctures and sealed compositions. The active ingredient may be dissolved or suspended in a pharmaceutically acceptable liquid carrier such as water, an organic solvent, a mixture of the two or a pharmaceutically acceptable oil or fat. The liquid carrier may contain other suitable pharmaceutical additives such as solubilizers, emulsifiers, buffers, preservatives, sweeteners, flavoring agents, suspending agents, thickening agents, pigments, viscosity regulators, stabilizing formation of osmotic pressure-regulating agents. Suitable examples of liquid carriers for oral and parenteral administration include water (partially containing additives as described above, e.g., cellulose derivatives, preferably carboxymethyl cellulose sodium salt solution), alcohols (including monohydric alcohols and polyhydric alcohols, e.g., ethylene glycol) and their derivatives, and oils (e.g., fractionated coconut oil and arachis oil). The carrier for parenteral administration may also be oils such as ethyl oleate and isopropyl myristate. Sterile liquid carriers are used in sterile liquid compositions for parenteral administration. The liquid carrier for the pressurized composition may be a halocarbon or other pharmaceutically acceptable propellant. Sterile solution or suspension liquid pharmaceutical compositions may be used, for example, for intravenous, intramuscular, intraperitoneal or subcutaneous injection. The suspension may be formulated according to techniques known in the art using a suitable dispersing or wetting agent (such as tween 80) and suspending agent.
To obtain a stable water-soluble dosage form, the compound or pharmaceutically acceptable salt thereof may be dissolved in an aqueous solution of an organic or inorganic acid, such as a 0.3M succinic acid or citric acid solution. Alternatively, the acidic derivative may be dissolved in a suitable alkaline solution. If a soluble form is not available, the compound may be dissolved in a suitable co-solvent or combination thereof. Examples of such suitable cosolvents include, but are not limited to, ethanol, propylene glycol, polyethylene glycol 300, polysorbate 80, glycerol, polyoxyethylene fatty acid esters, fatty alcohols or glycerol hydroxy fatty acid esters, and the like, at concentrations ranging from 0-60% total volume.
Other suitable excipients or carriers that may be used in the above-mentioned compositions are found in standard pharmacological textbooks, for example in "Remington's Pharmaceutical Sciences", 19 th edition.
In order to prevent and treat SARS-CoV-2 induced disease, such as novel coronavirus pneumonia, in monotherapy the compounds of formula I of the invention, or pharmaceutically acceptable salts thereof, are useful in a dosage range of between about 0.01 and about 100mg/kg body weight per day, preferably between 0.5 and 75mg/kg body weight per day. It will be appreciated by those skilled in the art that when a compound of formula I or a pharmaceutically-acceptable salt thereof of the present invention is used in combination with other therapeutic agents, the dosage may be suitably reduced. Typically, the pharmaceutical composition of the invention will be administered about 1 to 5 times per day, or another continuous infusion. Such drugs may be used as chronic or acute treatments. Representative formulations will contain from about 5% to about 95% active ingredient (weight/weight). Preferably, such formulations contain from about 20% to about 80% of the active compound.
It will be appreciated by those skilled in the art that higher or lower doses than those mentioned above may be required. The particular dosage and manner of treatment for a particular patient will depend on a variety of factors including the activity of the particular compound employed, the age, weight, sex, general health of the patient, diet, time of administration, metabolic rate, combination of drugs, and severity and course of the infection, the patient's predisposition to the infection, and the discretion of the treating physician. Generally, treatment is initiated at a small dose that is substantially lower than the optimal dose of the compound. The dosage is then increased by a small increase until the optimal effect is reached in this case. In general, it is desirable to administer the compound in a concentration level that is generally sufficient to produce an effective antiviral result, but that does not cause any deleterious or adverse side effects.
The compounds of the general formula of the present invention can be prepared by the following general synthetic methods. Substituents in these synthetic methods are as defined above.
The process flow comprises the following steps:
in some embodiments of the invention, the preparation method is as follows:
step I-1: preparation of Compound 1
NH in L configuration at room temperature 2 CHR 2 COOH (1.0 eq.) was dissolved in an appropriate amount of methanol and thionyl chloride (1.2 eq.) was slowly added under an ice water bath. Stirring at room temperature for 10min, and transferring to 70 ℃ oil bath for reaction for 3h. After the reaction, the solvent was removed under reduced pressure, and after the product was dissolved in an appropriate amount of dichloromethane, the pH was adjusted to weakly alkaline with TEA in an ice-water bath, boc-NHCHR of L configuration was added in sequence 3 COOH (1.0 eq), EDCI (1.2 eq), HOBt (1.2 eq) and TEA (4.0 eq) were transferred to room temperature for reaction for 12h. After the reaction is completed, water, saturated citric acid solution and saturated NaHCO are sequentially used 3 The organic phase was washed with solution, saturated sodium chloride. The combined organic phases were dried over anhydrous sodium sulfate, the solvent was distilled off under reduced pressure, and the obtained crude product was purified by flash chromatography to give the objective compound 1.
Step I-2: preparation of Compound 2
Compound 1 (1.0 eq.) was dissolved in anhydrous DCM and TFA (15.0 eq.) was slowly added dropwise under ice-water bath and allowed to react for 3h at room temperature. After the reaction was completed, DCM and TFA were removed by distillation under reduced pressure. Dissolving the product with anhydrous DCM, regulating pH with TEA in ice water bath to slightly alkaline, and sequentially adding corresponding R 1 COOH (1.0 eq), EDCI (1.2 eq), HOBt (1.2 eq) and TEA (4.0 eq) were transferred to room temperature for reaction for 12h. Water, saturated citric acid and saturated NaHCO are sequentially used after the reaction is finished 3 The organic phase was washed with saturated sodium chloride. The combined organic phases were dried over anhydrous sodium sulfate, the solvent was distilled off under reduced pressure by filtration, and the obtained crude product was purified by flash chromatography to give compound 2.
Step I-3: preparation of Compound 3
Sodium borohydride (15.0 eq) was slowly added to a methanol solution of compound 2 (1.0 eq) several times in an ice water bath and stirred at room temperature for 2 hours. After the reaction was completed, the reaction was quenched by adding a saturated aqueous ammonium chloride solution, and methanol was removed under reduced pressure. The water-soluble impurities were removed by extraction with DCM and water, the combined organic phases were washed with saturated sodium chloride solution, dried over anhydrous sodium sulfate and concentrated, and the crude product obtained was purified by flash chromatography to give the title compound 3.
Step I-4: preparation of Compound 4
To a solution of compound 3 (1.0 eq) in anhydrous DCM was added DMP (1.2 eq) and stirred for 2 hours. After completion of the reaction, the reaction was quenched by addition of saturated sodium bicarbonate and sodium thiosulfate (2.0 eq.) was added and the organic phase was stirred until clear. The combined organic phases were dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the crude product was purified by flash chromatography to give the title compound 4.
As demonstrated in the following examples, the compounds of the present invention or pharmaceutically acceptable salts thereof have better activity in inhibiting novel coronaviruses, and lower cytotoxicity, i.e., higher safety, and can be used for preventing and/or treating diseases caused by SARS-CoV-2 infection, such as novel coronavirus pneumonia.
Detailed Description
The invention will be further illustrated with reference to specific examples. It is to be understood that these examples are illustrative of the present invention and are not intended to limit the scope of the present invention. Further, it is understood that various changes and modifications of the invention will become apparent to those skilled in the art upon reading the description herein, and such equivalents are intended to fall within the scope of the invention as defined by the appended claims.
The temperature is provided in degrees celsius in the examples below. Unless otherwise stated, solution percentages represent weight versus volume, and solution ratios represent volume versus volume. The structure of the compounds in the examples was determined by nuclear magnetic resonance.
Nuclear magnetic resonance spectrum @ 1 H NMR 13 C NMR) was measured with a Bruker 400 spectrometer at a field strength of 400 MHz. Chemical shift is expressed in parts per million (ppm, delta) down-shifted relative to the internal standard tetramethylsilane standard. 1 The multiplicity of peaks in H-NMR is shown below: s = single peak; d = double peak; t = triplet; m=multiple peaks. Coupling constants are expressed in Hz. The solvent peak refers to the internal deuterated reagent. The commercial reagents used are all from their respective sourcesFrom the suppliers, if conditions for treatment are present, are described herein. Dichloromethane (DCM) was obtained by distillation of calcium hydride prior to use.
The following abbreviations are used in the present invention: meOH: methanol; boc: t-butoxycarbonyl; TEA: triethylamine; EA: ethyl acetate; DMP: dess-martin reagent; PE: petroleum ether; EDCI:1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride; HOBT: 1-hydroxybenzotriazole hydrate; DBU:1, 8-diazabicyclo undec-7-ene. In addition, "L" represents a naturally occurring amino acid.
Example 1 preparation of Compound 4-1
Step 1 preparation of Compound 1
L-phenylalanine (5.00 g,30.3 mmol) was taken in a 500mL round bottom flask, dissolved in an appropriate amount of MeOH, and thionyl chloride (2.6 mL,35.8 mmol) was slowly added dropwise under ice water bath and the mixture was brought to reflux at 70℃for 3h. After the reaction was completed, the resulting white solid was concentrated under reduced pressure, dissolved in an appropriate amount of anhydrous DCM, and pH was adjusted to weak base with TEA under ice water bath. Boc-L-leucine (7.42 g,29.8 mmol), EDCI (6.84 g,35.7 mmol), HOBt (4.82 g,35.7 mmol) and TEA (17.0 mL,104.0 mmol) were added sequentially at room temperature and reacted for 12h. After completion of the reaction, the mixture was extracted with water (2X 200 mL), a saturated citric acid solution (2X 200 mL), a saturated sodium bicarbonate solution (2X 200 mL), and a saturated brine (2X 200 mL) in this order. The combined organic phases were dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the crude product was purified by flash chromatography (PE: ea=6:1) to give compound 1 (6.20 g, yield 53.1%) as a white solid.
1 H NMR(400MHz,CDCl 3 )δ7.34–7.16(m,3H),7.11(d,J=7.1Hz,2H),6.72(d,J=6.6 Hz,1H),5.03(d,J=6.8Hz,1H),4.84(dd,J=13.0,6.1Hz,1H),4.11(d,J=7.1Hz,1H),3.70(d, J=10.4Hz,3H),3.10(qd,J=13.8,6.0Hz,2H),1.72–1.52(m,2H),1.38(d,J=38.8Hz,10H), 0.91(t,J=6.0Hz,6H)。
13 C NMR(101MHz,CDCl 3 )δ172.30,171.73,155.54,135.83,129.29,128.51,127.06,79.93, 53.19,53.08,52.24,41.24,37.91,28.29,24.65,22.87,21.96。
Step 2 preparation of Compound 2
Compound 1 (1.00 g,2.55 mmol) was dissolved in an appropriate amount of anhydrous DCM and trifluoroacetic acid (3.00 mL,40.4 mmol) was slowly added and stirred at room temperature for 2h. After the reaction was completed, the volatile solvent was removed under reduced pressure. The resulting oily liquid was dissolved in an appropriate amount of anhydrous DCM and the pH was adjusted to slightly alkaline with TEA under an ice-water bath. P-methoxy cinnamic acid (0.45 g,2.55 mmol), EDCI (0.59 g,3.06 mmol), HOBt (0.41 g,3.06 mmol) and TEA (1.4 mL,10.2 mmol) were added sequentially at room temperature and reacted for 12h. After completion of the reaction, the mixture was extracted with water (2X 50 mL), a saturated citric acid solution (2X 50 mL), a saturated sodium bicarbonate solution (2X 50 mL), and a saturated brine (2X 50 mL) in this order. The combined organic phases were dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the crude product was purified by flash chromatography (PE: ea=4:1) to give compound 2 (0.60 g, 52.0% yield) as a white solid.
1 H NMR(400MHz,CDCl 3 )δ7.63–7.54(m,1H),7.43(t,J=5.8Hz,2H),7.24–7.14(m, 3H),7.12–7.07(m,2H),7.02(d,J=7.9Hz,1H),6.84(d,J=8.8Hz,2H),6.56(d,J=8.4Hz,1H), 6.31(t,J=11.9Hz,1H),4.84(dd,J=14.1,6.3Hz,1H),4.68(td,J=8.5,5.6Hz,1H),3.81(d,J= 4.2Hz,3H),3.70(s,3H),3.12(dd,J=13.8,5.9Hz,1H),3.04(dd,J=13.8,6.6Hz,1H),1.74– 1.54(m,3H),0.93(dd,J=6.0,2.7Hz,6H)。
13 C NMR(101MHz,CDCl 3 )δ172.14,171.72,166.22,160.96,141.25,135.78,129.46, 129.30,128.56,127.45,127.01,117.85,114.26,55.33,53.43,52.29,51.62,41.11,37.92,24.78, 22.89,22.25。
Step 3 preparation of Compound 3
Compound 2 (0.60 g,1.33 mmol) was dissolved in an appropriate amount of MeOH and sodium borohydride (0.75 g, 20.0 mmol) was slowly added to the solution in an ice-water bath and reacted at room temperature for 1h. After the reaction is completed, a proper amount of saturated ammonium chloride solution is added for quenching. The solvent was distilled off under reduced pressure, extracted with DCM, the water-soluble impurities were removed, and the DCM layer was collected over anhydrous Na 2 SO 4 After the drying treatment, filtration is carried out. The crude product was purified by flash chromatography on silica gel (PE: ea=2:1) to give compound 3 (0.40 g, 70.8% yield) as a white solid.
1 H NMR(400MHz,MeOD)δ7.51(dd,J=12.2,3.4Hz,3H),7.26–7.17(m,4H),7.15– 7.07(m,1H),6.93(d,J=8.7Hz,2H),6.52(d,J=15.8Hz,1H),4.55–4.44(m,1H),4.17–4.03 (m,1H),3.81(s,3H),3.52(t,J=7.1Hz,2H),2.90(dt,J=15.1,7.5Hz,1H),2.80–2.70(m,1H), 1.70–1.59(m,1H),1.58–1.48(m,2H),0.91(dt,J=23.5,11.8Hz,6H)。
13 C NMR(101MHz,MeOD)δ173.13,167.47,161.29,140.71,138.26,129.16,129.03, 127.97,127.44,125.87,117.58,114.00,62.64,54.48,52.82,52.04,40.63,36.51,24.56,22.05, 20.73。
Step 4 preparation of Compound 4-1
Compound 3 (0.10 g,0.24 mmol) was dissolved in an appropriate amount of anhydrous DCM and dess-Martin oxidant (0.12 g,0.29 mmol) was added at room temperature. After the reaction was monitored by TLC to completion, the reaction was quenched by addition of an appropriate amount of saturated sodium bicarbonate solution and sodium thiosulfate, and stirred at room temperature for 2h. Extraction with DCM, removal of water-soluble impurities, collection of DCM layer, passage over anhydrous Na 2 SO 4 After the drying treatment, filtration is carried out. The crude product was purified by flash chromatography on silica gel (PE: ea=3:1) to give compound 4-1 as a white solid (800 mg, 80.0% yield).
1 H NMR(400MHz,CDCl3)δ9.52(s,1H),7.56–7.43(m,1H),7.36(d,J=8.7Hz,2H),7.14 (d,J=7.5Hz,3H),7.07(d,J=1.2Hz,4H),6.79(d,J=8.6Hz,2H),6.24–6.17(m,1H),4.65– 4.56(m,1H),4.55–4.46(m,1H),3.75(s,3H),3.11–3.02(m,1H),3.01–2.90(m,1H),1.68– 1.48(m,3H),0.86(dd,J=5.8,4.8Hz,6H)。
13 C NMR(101MHz,CDCl3)δ197.76,171.62,165.33,160.07,140.56,134.72,128.48, 128.27,127.71,126.25,125.99,116.46,113.29,58.81,54.33,50.55,39.88,33.96,23.80,21.84, 21.19。
EXAMPLE 2 preparation of Compound 4-2
The preparation was identical to compound 4-1 (760 mg, 77.0% yield).
1 H NMR(400MHz,CDCl 3 )δ9.59(s,1H),7.82(d,J=7.0Hz,2H),7.60(dd,J=13.3,7.5Hz, 4H),7.45(t,J=7.1Hz,2H),7.40(d,J=6.3Hz,1H),7.24(d,J=7.1Hz,1H),7.13(dt,J=7.1,5.7 Hz,5H),6.92(d,J=8.1Hz,1H),4.85–4.71(m,1H),4.60(d,J=6.9Hz,1H),3.19–3.08(m,1H), 3.07–2.94(m,1H),1.81–1.63(m,3H),0.96(s,6H)。
13 C NMR(101MHz,CDCl 3 )δ198.70,172.59,167.21,144.73,139.87,135.72,132.19, 129.24,128.97,128.71,128.12,127.75,127.22,127.05,59.88,52.00,40.99,34.96,24.96,22.88, 22.27。
Example 3: preparation of Compound 4-3
The preparation method was the same as for compound 4-1 (440 mg, 45.0% yield).
1 H NMR(400MHz,CDCl 3 )δ9.50(s,1H),8.41–8.33(m,1H),7.47–7.41(m,1H),7.40– 7.34(m,1H),7.22–7.17(m,2H),7.14–7.04(m,5H),6.85–6.75(m,1H),5.97–5.85(m,1H), 4.55–4.39(m,2H),3.70(s,2H),3.11–3.03(m,1H),2.96–2.85(m,1H),1.58–1.32(m,3H), 0.81–0.72(m,6H)。
13 C NMR(101MHz,CDCl 3 )δ198.80,172.20,171.98,136.39,135.85,129.27,128.74, 127.08,123.75,122.78,120.17,118.44,111.56,108.42,59.75,51.46,40.06,34.86,33.26,24.61, 22.74,21.85。
Example 4: preparation of Compounds 4-4
The preparation was carried out in the same manner as in compound 4-1 (600 mg, yield 61.0%).
1 H NMR(400MHz,CDCl 3 )δ9.62(s,1H),8.58(ddd,J=4.7,1.5,0.9Hz,1H),8.26(d,J= 8.4Hz,1H),8.14(d,J=7.8Hz,1H),7.88(td,J=7.7,1.7Hz,1H),7.48(ddd,J=7.6,4.8,1.2Hz, 1H),7.09(d,J=6.7Hz,5H),6.98(d,J=6.9Hz,1H),4.67(dt,J=13.7,4.5Hz,2H),3.16(dd,J= 14.1,6.4Hz,1H),3.07(dd,J=14.1,7.1Hz,1H),1.82(dd,J=10.4,5.0Hz,1H),1.76–1.63(m, 2H),0.94(dd,J=10.7,6.3Hz,6H)。
13 C NMR(101MHz,CDCl 3 )δ198.85,172.02,164.61,149.03,148.28,137.41,135.59, 129.22,128.58,126.93,126.58,122.55,59.70,51.54,40.25,34.93,24.81,22.97,21.94。
Example 5: preparation of Compounds 4-5
The preparation was carried out in the same manner as in compound 4-1 (810 mg, yield 81.9%).
1 H NMR(400MHz,CDCl 3 )δ9.78–9.36(m,1H),7.84–7.67(m,2H),7.34–6.99(m,9H), 4.90–4.69(m,1H),4.65–4.35(m,1H),3.44–2.82(m,2H),1.69(m,3H),0.93(s,6H)。
13 C NMR(101MHz,CDCl 3 )δ198.58,172.70,166.39,135.69,129.63,129.55,129.22, 128.71,127.08,115.71,115.49,59.93,52.06,41.00,34.90,24.92,22.84,22.18。
Example 6: preparation of Compounds 4-6
The preparation was identical to compound 4-1 (560 mg, 58.2% yield).
1 H NMR(400MHz,CDCl 3 )δ9.58(s,1H),7.35–7.21(m,3H),7.15(d,J=7.2Hz,2H),6.95 (d,J=6.8Hz,1H),6.13(d,J=8.1Hz,1H),4.59(d,J=6.8Hz,1H),4.50(d,J=5.7Hz,1H),3.99 (d,J=10.6Hz,2H),3.45–3.33(m,2H),3.14(d,J=6.4Hz,1H),3.09(d,J=7.2Hz,1H),2.32(s, 1H),1.66(tdd,J=26.7,17.4,12.5Hz,7H),0.91(t,J=6.8Hz,6H)。
13 C NMR(101MHz,CDCl 3 )δ198.52,174.53,172.48,135.65,129.24,128.77,127.16,67.14, 59.79,51.31,41.93,41.06,34.91,29.20,28.95,24.86,22.89,22.15。
Example 7: preparation of Compounds 4-7
The preparation was identical to compound 4-1 (660 mg, 67.8% yield).
1 H NMR(400MHz,CDCl3)δ9.60(s,1H),7.66(d,J=7.5Hz,2H),7.38(d,J=8.2Hz,2H), 7.17(s,3H),7.12(s,2H),6.98(s,1H),6.88–6.75(m,1H),4.77–4.66(m,1H),4.65–4.57(m, 1H),3.20–3.10(m,1H),3.10–2.99(m,1H),1.77–1.59(m,3H),0.93(s,6H)。
13 C NMR(101MHz,CDCl3)δ198.45,172.40,166.35,138.20,135.53,131.90,129.21, 128.84,128.74,128.60,127.14,59.86,52.03,41.05,34.98,24.92,22.83,22.21。
Example 8: preparation of Compounds 4-8
The preparation method was the same as for compound 4-1 (300 mg, yield 31.5%).
1 H NMR(400MHz,MeOD)δ9.58(s,1H),8.13(s,1H),7.64–7.61(m,1H),7.46(s,1H), 7.31(d,J=2.9Hz,2H),7.17(dd,J=5.8,3.0Hz,5H),6.58(d,J=2.9Hz,1H),4.46(s,1H),4.17–4.04(m,1H),3.27–3.18(m,1H),3.00–2.91(m,1H),1.73(s,3H),0.98–0.94(m,6H)。
13 C NMR(101MHz,MeOD)δ199.19,174.05,173.42,173.26,138.21,136.52,129.04, 128.32,127.95,127.55,126.51,126.05,125.86,120.38,110.85,102.35,60.15,54.88,40.57,34.05, 24.70,22.35,21.30。
Example 9: preparation of Compounds 4-9
The preparation was carried out in the same manner as in compound 4-1 (350 mg, yield 36.0%).
1 H NMR(400MHz,CDCl3)δ9.64(s,1H),9.43–9.33(m,1H),7.70–7.61(m,1H),7.48–7.40(m,1H),7.34–7.29(m,1H),7.09(s,7H),6.97–6.93(m,1H),6.88–6.79(m,1H),4.86–4.66(m,2H),3.21–3.04(m,2H),1.77–1.69(m,3H),0.94(t,J=6.0Hz,6H)。
13 C NMR(101MHz,CDCl3)δ198.69,161.75,160.66,136.42,135.29,129.20,128.68, 127.10,124.88,122.15,120.83,111.99,103.35,59.79,51.58,41.02,35.10,24.90,22.86,22.21。
Example 10: preparation of Compounds 4-10
The preparation was identical to compound 4-1 (510 mg, 52.3% yield).
1 H NMR(400MHz,CDCl 3 )δ9.44(s,1H),7.91(t,J=6.2Hz,1H),7.87(s,1H),7.79(d,J=7.5Hz,1H),7.33(dd,J=4.0,2.3Hz,1H),7.23–7.15(m,3H),7.11–7.03(m,2H),6.64(d,J= 1.1Hz,1H),4.72(dd,J=13.7,8.4Hz,1H),4.27(q,J=7.0Hz,1H),3.06(dd,J=14.1,6.8Hz, 1H),2.97(dd,J=14.1,7.5Hz,1H),1.74–1.67(m,2H),1.57(td,J=9.9,4.9Hz,1H),0.86(dd,J =6.4,3.5Hz,6H)。
13 C NMR(101MHz,CDCl 3 )δ198.75,174.00,162.89,145.50,143.58,135.85,129.10, 128.67,127.01,121.78,108.58,60.15,51.96,40.81,34.77,24.71,22.83,21.69。
Example 11: preparation of Compounds 4-11
The preparation was identical to compound 4-1 (360 mg, 36.8% yield).
1 H NMR(400MHz,CDCl 3 )δ9.52–9.41(m,1H),9.09–8.94(m,1H),7.27–7.25(m,1H), 7.22–7.19(m,1H),7.08–7.00(m,5H),6.72–6.62(m,1H),6.41–6.34(m,1H),6.33–6.24(m, 1H),4.66–4.55(m,1H),4.52–4.38(m,1H),3.11–2.99(m,1H),2.99–2.88(m,1H),1.65– 1.59(m,2H),1.55–1.50(m,1H),0.84(s,6H)。
13 C NMR(101MHz,CDCl 3 )δ199.13,173.24,165.27,135.71,129.28,128.71,127.02, 121.56,119.08,107.25,59.94,51.35,40.69,34.90,24.81,22.83,22.10。
Example 12: preparation of Compounds 4-12
The preparation was carried out in the same manner as in compound 4-1 (810 mg, yield 82.1%).
1 H NMR(400MHz,CDCl 3 )δ9.59(d,J=2.4Hz,1H),7.74–7.67(m,2H),7.43(t,J=8.5Hz, 2H),7.18–7.13(m,3H),7.12–7.04(m,3H),6.80–6.68(m,2H),5.84(dt,J=17.6,3.5Hz,1H), 5.37(dd,J=11.1,5.7Hz,1H),4.79–4.68(m,1H),4.66–4.56(m,1H),3.20–3.09(m,1H),3.03 (dd,J=14.2,7.4Hz,1H),1.79–1.62(m,3H),0.98–0.88(m,6H)。
13 C NMR(101MHz,CDCl 3 )δ198.68,172.45,167.06,141.09,135.86,135.64,132.54, 129.23,128.71,127.49,127.07,126.34,116.27,59.84,51.87,40.93,34.97,24.92,22.87,22.25。
Example 13: preparation of Compounds 4-13
The preparation was identical to compound 4-1 (750 mg, 76.3% yield).
1 H NMR(400MHz,CDCl 3 )δ9.58(s,1H),7.35–7.20(m,3H),7.15(d,J=7.1Hz,2H),7.00 (d,J=6.5Hz,1H),5.94(d,J=8.0Hz,1H),4.63–4.54(m,1H),4.49(dd,J=8.3,2.7Hz,1H), 3.15(dd,J=14.2,6.4Hz,1H),3.07(dd,J=14.2,7.2Hz,1H),2.06(dd,J=8.7,5.7Hz,1H),1.77 (d,J=9.4Hz,4H),1.70–1.55(m,3H),1.51(dd,J=14.7,6.6Hz,1H),1.44–1.32(m,2H),1.25 (dd,J=10.8,7.8Hz,2H),0.90(dd,J=9.4,6.2Hz,6H)。
13 C NMR(101MHz,CDCl 3 )δ198.72,176.30,172.58,135.72,129.25,128.74,127.17,59.76, 51.16,45.20,40.82,34.93,29.67,29.40,25.65,25.58,24.83,22.85,22.12。
Example 14: preparation of Compounds 4-14
The preparation method was the same as for compound 4-1 (400 mg, 40.5% yield).
1 H NMR(400MHz,CDCl 3 )δ9.54(s,1H),7.89–7.83(m,1H),7.38(dd,J=9.9,6.1Hz,2H), 7.31–7.24(m,1H),7.17(d,J=6.5Hz,2H),7.12–7.04(m,3H),4.72(d,J=7.4Hz,1H),4.49(d, J=6.9Hz,1H),3.10(d,J=6.3Hz,1H),3.06–2.93(m,1H),1.74–1.61(m,3H),0.91(dd,J=5.6, 3.7Hz,6H)。
13 C NMR(101MHz,CDCl 3 )δ198.73,172.92,163.05,136.54,135.81,129.24,129.09, 128.68,127.04,126.45,126.29,59.99,51.81,40.86,34.89,24.89,22.86,22.11。
Example 15: preparation of Compounds 4-15
The preparation was identical to compound 4-1 (760 mg, 77.0% yield).
1 H NMR(400MHz,CDCl 3 )δ9.62(s,1H),7.64–7.53(m,4H),7.26(s,2H),7.13(s,3H), 6.92–6.82(m,1H),6.75–6.61(m,1H),4.74–4.60(m,2H),3.22–3.12(m,1H),3.11–2.99(m, 1H),1.73(s,3H),0.98–0.88(m,6H)。
13 C NMR(101MHz,CDCl 3 )δ198.37,172.23,166.43,135.44,131.85,129.22,128.62, 127.16,59.82,51.96,41.05,35.01,24.88,22.83,22.22。
Example 16: preparation of Compounds 4-16
The preparation was identical to compound 4-1 (780 mg, 78.5% yield).
1 H NMR(400MHz,CDCl 3 )δ9.59(s,1H),7.74(d,J=8.0Hz,2H),7.51(d,J=7.3Hz,1H), 7.42(t,J=7.5Hz,2H),7.15(d,J=5.6Hz,3H),7.11(d,J=7.0Hz,2H),7.06(d,J=6.9Hz,1H), 6.72(d,J=8.1Hz,1H),4.74(s,1H),4.61(d,J=7.0Hz,1H),3.12(d,J=6.2Hz,1H),3.05(d,J= 7.3Hz,1H),1.79–1.59(m,3H),0.94(t,J=4.8Hz,6H)。
13 C NMR(101MHz,CDCl 3 )δ198.60,172.47,167.28,135.62,133.61,131.96,129.17, 128.45,127.19,59.76,51.66,40.77,34.87,24.99,22.55,21.99。
Example 17: preparation of Compounds 4-17
The preparation was identical to compound 4-1 (660 mg, 67.1% yield).
1 H NMR(400MHz,CDCl 3 )δ9.52(t,J=8.1Hz,1H),8.23(dd,J=6.3,3.4Hz,1H),7.92– 7.79(m,2H),7.50(ddd,J=11.0,7.4,2.3Hz,3H),7.40–7.30(m,1H),7.24(dd,J=15.7,8.0Hz, 1H),7.15(ddd,J=7.6,5.8,4.3Hz,3H),7.09(dd,J=5.0,2.7Hz,2H),6.67(d,J=8.3Hz,1H), 4.95–4.76(m,1H),4.53(td,J=6.8,4.6Hz,1H),3.14–3.02(m,1H),3.01–2.90(m,1H),1.79– 1.58(m,3H),0.99(dd,J=8.7,6.0Hz,6H)。
13 C NMR(101MHz,CDCl 3 )δ198.64,172.35,169.59,135.75,133.67,133.34,131.08, 130.09,129.22,128.72,128.41,127.33,127.04,126.53,125.34,125.22,124.64,59.85,52.04, 41.19,34.84,25.00,22.89,22.26。
Example 18: preparation of Compounds 4-18
The preparation was carried out in the same manner as in compound 4-1 (480 mg, yield 48.2%).
1 H NMR(400MHz,CDCl 3 )δ9.68–9.56(m,1H),9.27(s,1H),8.98(t,J=19.2Hz,1H), 8.25(d,J=8.4Hz,1H),8.11–8.02(m,1H),7.22–7.00(m,6H),6.78(d,J=6.8Hz,1H),4.73 (dd,J=13.6,6.8Hz,1H),4.66(td,J=8.6,5.8Hz,1H),3.14(qd,J=14.2,6.7Hz,2H),1.79–1.63 (m,3H),0.94(dt,J=14.8,7.4Hz,6H)。
13 C NMR(101MHz,CDCl 3 )δ198.48,171.40,162.80,159.31,157.88,155.48,135.34, 129.21,128.67,127.08,118.65,59.69,51.74,40.59,34.96,24.83,22.90,21.99。
Example 19: preparation of Compounds 4-19
The preparation was carried out in the same manner as in compound 4-1 (880 mg, yield 90.0%).
1 H NMR(400MHz,CDCl 3 )δ9.58(s,1H),7.52(t,J=12.0Hz,1H),7.46–7.37(m,3H), 7.25–7.19(m,2H),7.15(ddd,J=11.3,6.5,4.0Hz,3H),7.01–6.88(m,3H),6.39(d,J=15.6Hz, 1H),4.79–4.68(m,1H),4.54(dd,J=13.8,7.0Hz,1H),3.13(dd,J=14.2,6.3Hz,1H),3.03(dd, J=14.2,7.4Hz,1H),1.75–1.59(m,3H),0.92(dd,J=15.5,10.2Hz,6H)。
13 C NMR(101MHz,CDCl 3 )δ198.71,172.95,165.91,164.86,162.37,140.42,135.82, 130.86,130.83,129.72,129.64,129.27,128.73,127.04,119.94,116.07,115.85,59.95,51.79, 41.21,34.92,24.88,22.84,22.27。
Example 20: preparation of Compounds 4-20
The preparation was identical to compound 4-1 (750 mg, 76.3% yield).
1 H NMR(400MHz,CDCl 3 )δ9.61(d,J=12.6Hz,1H),8.99(s,1H),8.71(d,J=4.6Hz,1H), 8.13–8.03(m,1H),7.41–7.34(m,1H),7.33–7.28(m,1H),7.15(dt,J=13.7,7.3Hz,6H),4.80 –4.61(m,2H),3.17(dd,J=14.1,6.3Hz,1H),3.08(dd,J=13.9,7.1Hz,1H),1.70(d,J=5.0Hz, 3H),0.95–0.89(m,6H)。
13 C NMR(101MHz,CDCl 3 )δ198.45,172.39,165.56,152.37,148.18,135.48,135.41, 129.24,128.74,127.15,123.52,59.87,52.07,40.96,34.96,24.93,22.83,22.13。
Example 21: preparation of Compounds 4-21
The preparation was carried out in the same manner as in compound 4-1 (730 mg, yield 74.5%).
1 H NMR(400MHz,CDCl 3 )δ9.64(s,1H),8.78–8.66(m,2H),7.57(ddd,J=8.3,5.5,1.7Hz, 2H),7.23–7.17(m,3H),7.15–7.11(m,2H),7.00(d,J=7.9Hz,1H),6.80(d,J=6.7Hz,1H), 4.75–4.64(m,2H),3.18(dd,J=14.2,6.5Hz,1H),3.11(dd,J=14.2,6.9Hz,1H),1.69(dt,J= 18.0,6.7Hz,3H),0.94(dt,J=10.4,5.2Hz,6H)。
13 C NMR(101MHz,CDCl 3 )δ198.22,172.01,165.35,150.56,140.68,135.27,129.23, 128.81,127.27,120.98,59.86,52.07,41.21,35.02,24.92,22.82,22.19。
Example 22: preparation of Compounds 4-22
The preparation was carried out in the same manner as in compound 4-1 (790 mg, yield 79.1%).
1 H NMR(400MHz,CDCl 3 )δ9.60(s,1H),8.23(d,J=11.3Hz,1H),7.84(t,J=9.8Hz,3H), 7.79(dd,J=8.6,1.5Hz,1H),7.54(ddd,J=15.0,10.8,3.7Hz,2H),7.21(d,J=7.1Hz,1H),7.17 –7.04(m,5H),6.98(d,J=8.2Hz,1H),4.92–4.75(m,1H),4.62(dd,J=13.8,7.0Hz,1H),3.14 (dd,J=14.2,6.3Hz,1H),3.02(dd,J=14.2,7.4Hz,1H),1.82–1.66(m,3H),1.02–0.90(m, 6H)。
13 C NMR(101MHz,CDCl 3 )δ198.70,172.59,167.57,135.66,134.91,132.54,130.74, 129.22,129.01,128.70,128.52,127.90,127.85,127.77,127.03,126.88,123.57,59.86,52.03, 41.03,34.97,24.97,22.90,22.30。
Implementation example 23: preparation of Compounds 4-23
The preparation was identical to compound 4-1 (680 mg, 67.8% yield).
1 H NMR(400MHz,CDCl 3 )δ9.61(d,J=12.6Hz,1H),8.99(s,1H),8.71(d,J=4.6Hz,1H), 8.13–8.03(m,1H),7.41–7.34(m,1H),7.33–7.28(m,1H),7.15(dt,J=13.7,7.3Hz,6H),4.80 –4.61(m,2H),3.17(dd,J=14.1,6.3Hz,1H),3.08(dd,J=13.9,7.1Hz,1H),1.70(d,J=5.0Hz, 3H),0.95–0.89(m,6H)。
13 C NMR(101MHz,CDCl 3 )δ198.72,172.24,171.28,135.79,134.43,129.28,129.04, 128.74,127.49,127.10,59.75,51.58,43.43,40.56,34.88,24.76,22.76,22.12。
Implementation example 24: preparation of Compounds 4-24
The preparation was identical to compound 4-1 (540 mg, 53.9% yield).
1 H NMR(400MHz,CDCl 3 )δ9.55(s,1H),7.31–7.22(m,5H),7.17(ddd,J=16.5,9.2,7.2 Hz,5H),6.89(d,J=6.9Hz,1H),5.93(t,J=22.9Hz,1H),4.55(q,J=6.9Hz,1H),4.51–4.38(m, 1H),3.13(dd,J=14.2,6.4Hz,1H),3.08–2.97(m,1H),2.96–2.85(m,2H),2.50–2.40(m,2H), 1.62–1.49(m,1H),1.48–1.32(m,2H),0.84(dd,J=15.4,8.5Hz,6H)。
13 C NMR(101MHz,CDCl 3 )δ198.67,172.41,172.27,140.45,135.74,129.29,128.76, 128.59,128.30,127.14,126.37,59.79,51.36,40.81,38.01,34.94,31.48,24.60,22.83,22.09。
Example 25: preparation of Compounds 4-25
The preparation was carried out in the same manner as in compound 4-1 (420 mg, yield 43.6%).
1 H NMR(400MHz,CDCl3)δ9.71(s,1H),9.58(d,J=1.6Hz,1H),7.32–7.25(m,1H),7.11 (t,J=5.7Hz,5H),6.93(s,1H),6.68–6.57(m,1H),6.43(d,J=8.3Hz,1H),6.29–6.18(m,1H), 4.78–4.61(m,2H),3.11(dd,J=14.1,6.5Hz,1H),3.04(dd,J=14.0,7.0Hz,1H),1.74–1.59(m, 3H),0.91(dd,J=11.8,5.7Hz,6H)。
13 C NMR(101MHz,CDCl3)δ198.96,172.58,161.04,135.56,129.21,128.63,127.03, 125.08,122.13,110.13,110.06,59.79,51.24,40.96,35.12,24.85,22.88,22.16。
Example 26: preparation of Compounds 4-26
The preparation was identical to compound 4-1 (450 mg, 46.0% yield).
1 H NMR(400MHz,CDCl 3 )δ9.61(s,1H),7.47(s,1H),7.20–7.13(m,3H),7.13–7.08(m, 3H),6.94(t,J=16.7Hz,1H),6.65(t,J=16.8Hz,1H),6.53(dd,J=3.3,1.6Hz,1H),4.73–4.60 (m,2H),3.16(dd,J=14.1,6.4Hz,1H),3.05(dd,J=14.1,7.2Hz,1H),1.78–1.56(m,3H),0.98– 0.88(m,6H)。
13 C NMR(101MHz,CDCl 3 )δ198.68,171.98,158.30,147.21,144.36,135.57,129.25, 128.65,127.01,115.03,112.32,59.78,51.03,40.77,35.00,24.77,22.89,22.09。
Example 27: preparation of Compounds 4-27
The preparation was identical to compound 4-1 (720 mg, 72.3% yield).
1 H NMR(400MHz,CDCl 3 )δ9.59(s,1H),7.51–7.42(m,2H),7.36(td,J=8.0,5.6Hz,1H), 7.23–7.14(m,4H),7.11(dt,J=11.6,5.4Hz,3H),7.02(d,J=8.2Hz,1H),4.72(dd,J=15.2,7.1 Hz,1H),4.60(q,J=6.9Hz,1H),3.15(dd,J=14.2,6.4Hz,1H),3.06(dd,J=14.2,7.3Hz,1H), 1.75–1.62(m,3H),0.99–0.86(m,6H)。
13 C NMR(101MHz,CDCl 3 )δ198.54,172.52,166.14,163.93,161.47,135.78,135.71, 135.58,130.26,130.19,129.22,128.74,127.13,122.64,122.61,118.98,118.77,114.74,114.51, 59.90,52.11,40.98,34.94,24.93,22.85,22.18。
Example 28: preparation of Compounds 4-28
The preparation was carried out in the same manner as in compound 4-1 (750 mg, yield 75.6%).
1 H NMR(400MHz,CDCl 3 )δ9.62(s,1H),8.01(td,J=7.9,1.6Hz,1H),7.50(tt,J=14.5,7.2 Hz,1H),7.31–7.22(m,1H),7.20–7.06(m,6H),7.01(t,J=9.3Hz,2H),4.78–4.61(m,2H), 3.17(dd,J=14.2,6.3Hz,1H),3.11–2.98(m,1H),1.84–1.56(m,3H),1.01–0.89(m,6H)。
13 C NMR(101MHz,CDCl 3 )δ198.78,171.99,163.49,161.95,159.49,135.59,133.86, 133.77,132.05,129.21,128.64,127.01,124.88,124.85,120.36,120.25,116.27,116.03,59.73, 51.99,40.53,34.94,24.84,22.91,22.08。
Example 29: preparation of Compounds 4-29
The preparation was carried out in the same manner as in compound 4-1 (820 mg, yield 83.2%).
1 H NMR(400MHz,CDCl 3 )δ9.58(s,1H),7.32–7.18(m,3H),7.15(d,J=6.9Hz,2H),7.07 (d,J=6.8Hz,1H),6.11(d,J=8.2Hz,1H),4.63–4.46(m,2H),3.15(dd,J=14.2,6.4Hz,1H), 3.10–2.98(m,1H),2.12(t,J=7.5Hz,2H),1.67–1.49(m,5H),0.96–0.86(m,9H)。
13 C NMR(101MHz,CDCl 3 )δ198.71,173.24,172.62,135.79,129.26,128.72,127.09,59.81, 51.33,40.92,38.33,34.93,24.80,22.81,22.15,19.05,13.69。
Example 30: preparation of Compounds 4-30
The preparation was identical to compound 4-1 (780 mg, 79.6% yield).
1 H NMR(400MHz,CDCl 3 )δ9.57(s,1H),7.32–7.20(m,3H),7.15(dd,J=7.3,2.9Hz,3H), 6.18(d,J=8.2Hz,1H),4.62–4.45(m,2H),3.15(dd,J=14.2,6.4Hz,1H),3.09–2.99(m,1H), 2.19–2.09(m,2H),1.67–1.46(m,5H),1.30(ddd,J=13.6,9.1,2.3Hz,4H),0.90(dd,J=13.8, 7.5Hz,9H)。
13 C NMR(101MHz,CDCl 3 )δ198.73,173.42,172.68,135.83,129.26,128.71,127.07,59.81, 51.35,40.94,36.42,34.92,31.39,25.31,24.80,22.80,22.37,22.17,13.94。
Example 31: preparation of Compounds 4-31
The preparation was identical to compound 4-1 (750 mg, 76.2% yield).
1 H NMR(400MHz,CDCl 3 )δ9.61(s,1H),7.69(d,J=15.8Hz,1H),7.53–7.43(m,1H), 7.33(dtd,J=11.7,7.6,4.0Hz,1H),7.28–7.23(m,2H),7.20–7.03(m,5H),6.97(d,J=7.0Hz, 1H),6.55(t,J=17.9Hz,1H),6.30(t,J=15.3Hz,1H),4.65(dt,J=8.4,4.5Hz,2H),3.16(dd,J= 14.1,6.4Hz,1H),3.06(dd,J=14.2,7.3Hz,1H),1.76–1.64(m,3H),0.93(dt,J=14.5,7.3Hz, 6H)。
13 C NMR(101MHz,CDCl 3 )δ198.64,172.35,165.84,162.92,160.02,135.59,135.04, 131.31,131.22,129.68,129.28,128.77,127.10,124.48,124.44,122.77,122.70,116.32,116.10, 59.81,51.65,40.88,35.02,24.83,22.85,22.19。
Example 32: preparation of Compounds 4-32
The preparation was carried out in the same manner as in compound 4-1 (620 mg, yield 65.4%).
1 H NMR(400MHz,CDCl 3 )δ9.61(s,1H),7.60–7.46(m,1H),7.30(tt,J=9.1,4.6Hz,1H), 7.27–7.20(m,3H),7.20–7.11(m,4H),7.08–7.00(m,2H),6.47(dd,J=24.2,6.4Hz,1H),6.42 (dd,J=15.6,8.4Hz,1H),4.73–4.55(m,2H),3.15(dd,J=14.2,6.4Hz,1H),3.07(dd,J=14.2, 7.2Hz,1H),1.75–1.55(m,3H),0.99–0.90(m,6H)。
13 C NMR(101MHz,CDCl 3 )δ198.56,172.49,165.54,164.25,161.79,140.58,136.92, 135.60,130.46,130.38,129.28,128.77,127.10,123.89,121.35,116.88,116.66,114.23,114.02, 59.85,51.73,41.08,35.01,24.85,22.85,22.21。
Example 33: preparation of Compounds 4-33
The preparation was identical to compound 4-1 (510 mg, 49.5% yield).
1 H NMR(400MHz,CDCl 3 )δ9.61(s,1H),7.24–7.15(m,3H),7.14–7.06(m,3H),6.70(t,J =20.0Hz,1H),6.41(d,J=0.8Hz,1H),4.70(q,J=6.8Hz,1H),4.62(td,J=8.7,5.5Hz,1H), 3.21–3.06(m,2H),2.50(d,J=0.7Hz,3H),1.77–1.56(m,3H),0.99–0.87(m,6H)。
13 C NMR(101MHz,CDCl 3 )δ198.52,171.44,171.39,159.28,158.07,135.41,129.26, 128.73,127.12,101.43,59.72,51.58,40.58,35.03,24.77,22.87,21.92,12.35。
Example 34: preparation of Compounds 4-34
The preparation method was the same as for compound 4-1 (640 mg, 65.5% yield).
1 H NMR(400MHz,CDCl 3 )δ9.63(d,J=7.3Hz,1H),8.35–8.14(m,2H),7.96–7.80(m, 2H),7.25–7.18(m,3H),7.16–7.10(m,2H),6.90(t,J=11.5Hz,1H),6.68(d,J=7.0Hz,1H), 4.77–4.63(m,2H),3.15(qd,J=14.2,6.7Hz,2H),1.72–1.68(m,3H),1.00–0.90(m,6H)。
13 C NMR(101MHz,CDCl 3 )δ198.14,171.96,165.24,149.82,139.12,135.24,129.23, 128.83,128.35,127.29,123.80,59.86,52.25,41.37,35.07,24.95,22.82,22.22。
Example 35: preparation of Compounds 4-35
The preparation was identical to compound 4-1 (560 mg, 57.8% yield).
1 H NMR(400MHz,CDCl 3 )δ9.59(s,1H),7.77–7.64(m,2H),7.18–7.13(m,3H),7.10(dd, J=7.0,2.6Hz,2H),7.06(d,J=7.1Hz,1H),6.96–6.85(m,2H),6.54(d,J=8.2Hz,1H),4.76– 4.65(m,1H),4.61(dd,J=13.6,7.1Hz,1H),3.85(d,J=5.8Hz,3H),3.14(dd,J=14.1,6.2Hz, 1H),3.02(dd,J=14.1,7.4Hz,1H),1.78–1.59(m,3H),0.92(dt,J=8.9,4.2Hz,6H)。
13 C NMR(101MHz,CDCl 3 )δ198.71,172.54,166.98,162.57,135.67,129.23,129.00, 128.69,127.03,125.80,113.81,59.81,55.46,51.78,40.84,34.99,24.91,22.88,22.22。
Example 36: preparation of Compounds 4-36
The preparation method was the same as for compound 4-1 (300 mg, yield 80.0%).
1 H NMR(400MHz,DMSO-d6)δ9.54–9.42(m,1H),8.51(d,J=7.1Hz,1H),8.23(d,J= 8.1Hz,1H),7.57(d,J=7.4Hz,2H),7.50–7.35(m,4H),7.21(tt,J=13.2,6.7Hz,5H),6.74(d,J =15.8Hz,1H),4.48(dd,J=14.3,8.1Hz,1H),4.35–4.23(m,1H),3.16(dd,J=14.1,4.2Hz,1H), 2.84(dd,J=13.8,9.7Hz,1H),1.67–1.55(m,1H),1.45(dt,J=20.8,7.4Hz,2H),0.99–0.79(m, 6H)。
13 C NMR(101MHz,DMSO-d6)δ200.71,173.16,165.23,139.42,138.10,135.40,129.93, 129.69,129.43,128.65,127.96,126.73,122.51,60.07,51.39,41.59,33.75,24.74,23.41,22.08。
Example 37: preparation of Compounds 4-37
The preparation was identical to compound 4-1 (260 mg, 75.6% yield).
1 H NMR(400MHz,CDCl 3 )δ9.62(d,J=12.3Hz,1H),7.30–7.23(m,3H),7.15(t,J=8.0 Hz,2H),6.74(d,J=6.6Hz,1H),4.85(d,J=7.6Hz,1H),4.66(d,J=5.6Hz,1H),4.12(s,1H), 3.20–3.09(m,2H),1.70–1.60(m,2H),1.50(d,J=7.2Hz,1H),1.43(s,9H),0.93(dd,J=11.0, 5.1Hz,6H)。
13 C NMR(101MHz,CDCl 3 )δ198.35,172.84,155.59,135.49,129.33,128.77,127.17,59.66, 53.13,41.12,35.12,28.29,24.75,22.90,21.91。
Example 38: preparation of Compounds 4-38
The preparation method was the same as for compound 4-1 (430 mg, 75.0% yield).
1 H NMR(400MHz,CDCl 3 )δ9.58(s,1H),7.39–7.29(m,5H),7.28–7.20(m,3H),7.12(d, J=6.9Hz,2H),6.69(d,J=5.4Hz,1H),5.24(t,J=16.4Hz,1H),5.13–5.02(m,2H),4.71–4.57 (m,1H),4.21(d,J=4.2Hz,1H),3.20–3.03(m,2H),1.71–1.54(m,2H),1.53–1.41(m,1H), 0.90(dd,J=12.1,8.6Hz,6H)。
13 C NMR(101MHz,CDCl 3 )δ198.55,172.44,156.18,136.11,135.51,129.32,128.77, 128.59,128.30,128.08,127.18,67.19,59.70,53.44,41.20,35.03,24.69,22.88,21.95。
Example 39: preparation of Compounds 4-39
The preparation was carried out in the same manner as in compound 4-1 (450 mg, yield 68.0%).
1 H NMR(400MHz,CDCl 3 )δ9.58(d,J=5.9Hz,1H),7.32–7.23(m,3H),7.15(d,J=6.8 Hz,2H),6.86(d,J=6.8Hz,1H),6.16(t,J=10.1Hz,1H),4.65–4.56(m,1H),4.54–4.43(m, 1H),3.23–3.03(m,2H),2.15(d,J=7.5Hz,3H),1.87–1.68(m,6H),1.65–1.51(m,3H),0.91 (dd,J=7.8,6.3Hz,6H)。
13 C NMR(101MHz,CDCl 3 )δ198.44,174.28,172.44,135.57,129.23,128.80,127.20,59.82, 51.35,42.50,41.12,34.93,32.97,32.76,32.49,25.95,25.86,25.69,25.60,24.87,22.81,22.14。
Example 40: preparation of Compounds 4-40
The preparation was carried out in the same manner as in compound 4-1 (320 mg, yield 55.0%).
1 H NMR(400MHz,CDCl 3 )δ9.58(d,J=2.8Hz,1H),7.33–7.24(m,3H),7.16(dd,J=5.2, 3.1Hz,2H),6.81(d,J=6.6Hz,1H),5.87(t,J=9.8Hz,1H),4.65–4.57(m,1H),4.46(td,J=8.8, 5.7Hz,1H),3.20–3.04(m,2H),1.86–1.65(m,16H),1.63–1.48(m,2H),0.91(dt,J=10.0,5.1 Hz,6H)。
13 C NMR(101MHz,CDCl 3 )δ198.73,178.22,172.51,135.66,129.24,128.81,127.15,59.69, 51.10,40.58,39.09,36.41,35.00,28.02,24.91,22.93,22.08。
Example 41: preparation of Compounds 4-41
The preparation was carried out in the same manner as in compound 4-1 (550 mg, yield 68.2%).
1 H NMR(400MHz,CDCl 3 )δ9.55(s,1H),7.80(t,J=5.0Hz,1H),7.59(d,J=15.6Hz,1H), 7.42(d,J=6.7Hz,2H),7.26(dt,J=13.4,8.3Hz,4H),6.54(d,J=15.6Hz,1H),4.93–4.71(m, 1H),4.06(ddd,J=45.3,19.5,5.2Hz,2H),1.82–1.65(m,3H),0.94(dt,J=12.5,5.6Hz,6H)。
13 C NMR(101MHz,CDCl 3 )δ197.01,173.53,166.29,141.60,134.61,129.81,128.80, 127.89,120.30,51.86,50.02,41.31,24.89,22.91,22.21。
Example 42: preparation of Compounds 4-42
/>
The preparation method was the same as for compound 4-1 (320 mg, yield 65.0%).
1 H NMR(400MHz,CDCl 3 )δ9.61(d,J=14.5Hz,1H),7.60(d,J=15.0Hz,1H),7.47(s, 2H),7.40–7.21(m,5H),7.13(d,J=26.7Hz,3H),6.56–6.37(m,2H),4.67(t,J=17.2Hz,2H), 3.37(d,J=13.8Hz,1H),3.08(d,J=6.0Hz,1H),1.77–1.45(m,3H),0.90(d,J=32.5Hz,6H)。
13 C NMR(101MHz,CDCl 3 )δ198.09,172.64,165.95,141.90,134.55,134.10,133.89, 131.81,129.95,129.72,128.89,128.59,127.90,127.04,120.01,58.76,51.66,41.11,32.67,24.86, 22.87,22.29。
Example 43: preparation of Compounds 4-43
The preparation was carried out in the same manner as in compound 4-1 (340 mg, yield 55.0%).
1 H NMR(400MHz,CDCl 3 )δ9.64(d,J=19.1Hz,1H),7.93(t,J=14.8Hz,1H),7.66–7.59 (m,1H),7.50(t,J=11.5Hz,3H),7.35(dd,J=14.9,9.5Hz,5H),6.43–6.35(m,1H),4.87–4.69 (m,1H),4.60(dd,J=30.5,22.2Hz,1H),3.77–3.52(m,1H),3.17–2.97(m,1H),1.64–1.49(m, 3H),0.92(dd,J=15.3,9.2Hz,6H)。
13 C NMR(101MHz,CDCl 3 )δ197.80,172.53,165.93,142.10,134.45,133.41,130.03, 128.90,128.24,127.92,125.27,119.80,58.97,51.63,40.73,32.15,24.77,22.84,21.88。
Example 44: preparation of Compounds 4-44
The preparation method was the same as for compound 4-1 (800 mg, yield 90.0%).
1 H NMR(400MHz,CDCl 3 )δ9.64(s,1H),7.59(t,J=17.2Hz,1H),7.52–7.41(m,2H), 7.33(dd,J=5.8,4.0Hz,4H),6.86(d,J=8.3Hz,1H),6.50(d,J=15.6Hz,1H),4.83(dd,J=13.9, 8.1Hz,1H),4.47(dd,J=7.8,4.8Hz,1H),2.35–2.18(m,1H),1.84–1.61(m,3H),1.02–0.95 (m,9H),0.92(d,J=6.9Hz,3H)。
13 C NMR(101MHz,CDCl 3 )δ199.62,173.05,165.90,141.51,134.52,129.66,128.81, 128.66,127.89,127.73,120.02,63.35,51.77,41.15,28.78,24.73,22.72,22.19,18.95,17.68。
Example 45: preparation of Compounds 4-45
The preparation was carried out in the same manner as in compound 4-1 (400 mg, yield 49.0%).
1 H NMR(400MHz,CDCl 3 )δ9.56(d,J=24.7Hz,1H),7.58(t,J=15.2Hz,1H),7.48(d,J=6.3Hz,3H),7.39–7.26(m,3H),7.14(t,J=9.3Hz,2H),7.04(d,J=7.9Hz,2H),6.66(d,J=8.0 Hz,1H),6.46(d,J=15.6Hz,1H),4.69(t,J=15.9Hz,1H),4.63–4.37(m,1H),3.13(dd,J=14.1, 5.6Hz,1H),2.93(dd,J=14.0,7.8Hz,1H),1.63(ddd,J=34.5,19.3,6.0Hz,3H),1.05–0.86(m, 6H)。
13 C NMR(101MHz,CDCl 3 )δ198.42,172.80,166.07,142.03,134.45,134.36,132.87, 130.65,130.02,128.90,128.79,127.96,119.91,59.67,51.74,40.94,34.18,24.87,22.83,22.31。
Example 46: preparation of Compounds 4-46
The preparation method was the same as for compound 4-1 (850 mg, yield 80.0%).
1 H NMR(400MHz,CDCl 3 )δ9.58(d,J=14.7Hz,1H),7.62(d,J=15.6Hz,1H),7.52–7.43 (m,2H),7.34(dd,J=5.0,1.6Hz,3H),7.09–6.96(m,3H),6.77(dd,J=16.0,8.6Hz,2H),6.43 (dt,J=18.9,8.9Hz,2H),4.75–4.65(m,1H),4.63–4.55(m,1H),3.68(d,J=24.1Hz,3H),3.08 (dt,J=12.7,6.3Hz,1H),3.04–2.92(m,1H),1.77–1.55(m,3H),0.99–0.89(m,6H)。
13 C NMR(101MHz,CDCl 3 )δ198.89,172.46,165.94,158.62,141.93,134.55,130.32, 129.96,128.88,127.92,119.93,114.15,59.95,55.10,51.63,40.98,34.15,24.84,22.89,22.23。
Example 47: preparation of Compounds 4-47
The preparation was carried out in the same manner as in compound 4-1 (150 mg, yield 43.0%).
1 H NMR(400MHz,CDCl3)δ9.65(s,1H),7.60(dd,J=15.6,8.8Hz,1H),7.53–7.45(m, 3H),7.39–7.29(m,3H),7.24–7.10(m,3H),7.09–6.98(m,1H),6.42(ddd,J=38.7,24.8,8.2 Hz,2H),4.70(td,J=14.5,8.4Hz,2H),3.40(dd,J=14.1,5.7Hz,1H),3.08(dt,J=14.1,9.3Hz, 1H),1.73–1.54(m,3H),0.97–0.88(m,6H)。
13 C NMR(101MHz,CDCl3)δ198.05,172.54,165.95,141.98,135.64,134.53,133.06, 131.78,129.99,128.91,128.80,127.91,127.68,124.65,119.94,58.79,51.63,41.02,35.20,34.93, 24.85,22.88,22.26。
Example 48: preparation of Compounds 4-48
/>
The preparation was carried out in the same manner as in compound 4-1 (230 mg, yield 65.3%).
1 H NMR(400MHz,CDCl 3 )δ9.54(d,J=9.6Hz,1H),7.62(d,J=15.6Hz,1H),7.50–7.39 (m,2H),7.35–7.22(m,4H),6.90(d,J=8.4Hz,1H),6.53(dd,J=17.5,7.3Hz,1H),4.83–4.72 (m,1H),4.37(tt,J=34.8,6.6Hz,1H),1.86–1.50(m,10H),1.44(ddd,J=15.2,9.8,6.4Hz,1H), 1.41–1.25(m,2H),1.17–1.02(m,3H),1.01–0.93(m,6H)。
13 C NMR(101MHz,CDCl 3 )δ199.75,172.88,166.10,141.82,134.59,129.87,128.84, 127.89,120.17,56.86,51.71,41.17,36.00,33.88,33.63,32.50,26.24,26.05,25.95,24.90,22.88, 22.42。
Example 49: preparation of Compounds 4-49
The preparation was identical to compound 4-1 (230 mg, 56.0% yield).
1 H NMR(400MHz,CDCl 3 )δ9.60(t,J=7.3Hz,1H),7.59(dd,J=15.6,6.7Hz,1H),7.52– 7.43(m,2H),7.39–7.29(m,3H),7.23(t,J=7.0Hz,1H),7.18–7.10(m,2H),7.06–6.92(m, 2H),6.51(d,J=8.3Hz,1H),6.45(dd,J=15.6,6.1Hz,1H),4.76–4.57(m,2H),3.24(dd,J= 14.0,6.3Hz,1H),3.08(dd,J=14.2,7.4Hz,1H),1.75–1.51(m,3H),0.91(ddd,J=9.5,6.3,3.9 Hz,6H)。
13 C NMR(101MHz,CDCl 3 )δ198.04,172.64,165.92,141.84,134.59,131.91,131.87, 129.91,129.05,128.97,128.88,127.89,124.36,124.33,122.87,120.03,115.56,115.34,59.04, 51.66,41.11,29.71,28.30,24.84,22.86,22.25。
Example 50: preparation of Compounds 4-50
The preparation was identical to compound 4-1 (780 mg, 85.0% yield).
1 H NMR(400MHz,CDCl 3 )δ9.47(d,J=6.4Hz,1H),7.59(t,J=10.6Hz,2H),7.40(d,J= 7.5Hz,2H),7.27(dt,J=13.2,6.6Hz,3H),7.15(dt,J=11.7,7.0Hz,3H),7.08(t,J=6.1Hz,2H), 7.00(d,J=8.3Hz,1H),6.52(d,J=15.6Hz,1H),4.84(dd,J=14.0,7.6Hz,1H),4.37–4.23(m, 1H),2.69–2.53(m,2H),2.15(td,J=14.0,6.9Hz,1H),1.95–1.82(m,1H),1.82–1.64(m,3H), 0.97(dd,J=16.0,10.2Hz,6H)。
13 C NMR(101MHz,CDCl 3 )δ199.00,173.11,166.21,141.85,140.41,134.55,129.86, 128.82,128.55,128.45,127.91,126.30,120.18,58.52,51.92,41.30,31.50,30.26,24.94,22.86, 22.42。
Example 51: preparation of Compounds 4-51
The preparation method was the same as for compound 4-1 (500 mg, yield 46.0%).
1 H NMR(400MHz,CDCl 3 )δ9.57(s,1H),7.65–7.53(m,2H),7.44(t,J=8.4Hz,2H),7.35 –7.27(m,3H),7.21–7.15(m,1H),7.12(d,J=5.6Hz,2H),7.01(d,J=4.0Hz,1H),6.75(d,J= 8.0Hz,1H),6.48(dd,J=15.6,5.7Hz,1H),4.79–4.65(m,1H),4.45(dd,J=13.7,7.0Hz,1H), 3.17(td,J=14.6,5.6Hz,1H),3.03–2.87(m,1H),1.76–1.60(m,2H),1.53(dd,J=15.1,6.4Hz, 1H),0.98–0.85(m,6H)。
13 C NMR(101MHz,CDCl 3 )δ198.35,173.06,166.17,141.93,138.26,134.53,129.91, 129.35,128.87,127.92,127.47,127.18,119.96,59.78,51.79,40.93,34.31,24.89,22.83,22.28。
Example 52: preparation of Compounds 4-52
The preparation was carried out in the same manner as in compound 4-1 (600 mg, yield 68.0%).
1 H NMR(400MHz,DMSO-d6)δ9.50(d,J=21.4Hz,1H),8.58(t,J=9.4Hz,1H),8.23(d,J =8.0Hz,1H),7.58(t,J=7.0Hz,4H),7.43(dt,J=11.7,10.5Hz,7H),6.74(t,J=13.4Hz,1H), 4.40(ddd,J=21.5,15.5,9.9Hz,2H),3.26(dd,J=13.9,3.8Hz,1H),2.89(dt,J=26.6,13.2Hz, 1H),1.55(dd,J=12.6,6.2Hz,1H),1.50–1.30(m,2H),0.91–0.77(m,6H)。
13 C NMR(101MHz,DMSO-d6)δ200.43,173.21,165.23,139.46,135.35,130.63,129.95, 129.40,127.94,125.36,122.41,59.57,51.47,41.41,33.54,24.69,23.28,22.04。
Example 53: preparation of Compounds 4-53
The preparation was identical to compound 4-1 (350 mg, 72.0% yield).
1 H NMR(400MHz,CDCl 3 )δ9.60–9.49(m,1H),7.77(t,J=6.6Hz,1H),7.64–7.55(m, 1H),7.47–7.37(m,2H),7.30(ddd,J=14.4,5.9,1.6Hz,3H),6.89(dddd,J=23.1,19.1,14.6,5.1 Hz,5H),6.53–6.43(m,1H),4.73(dt,J=22.6,7.8Hz,1H),4.66–4.56(m,1H),3.18(td,J=14.1, 5.7Hz,1H),3.02–2.91(m,1H),1.70–1.44(m,3H),0.85(qdd,J=16.8,10.7,6.1Hz,8H)。
13 C NMR(101MHz,CDCl 3 )δ198.75,173.19,166.19,141.87,134.54,130.18,130.09, 129.90,128.86,128.84,127.92,124.92,120.09,116.44,116.23,114.00,113.79,59.56,51.98, 51.72,41.31,34.24,29.71,24.76,22.77,22.67,22.29。
Example 54: preparation of Compounds 4-54
The preparation was carried out in the same manner as in compound 4-1 (550 mg, yield 69.0%).
1 H NMR(400MHz,CDCl 3 )δ9.61(s,1H),7.61(d,J=15.6Hz,1H),7.49(d,J=6.7Hz,2H), 7.36(s,3H),7.16(d,J=7.0Hz,1H),7.13–7.05(m,2H),6.90(t,J=8.2Hz,2H),6.42(d,J=15.6 Hz,1H),6.35(d,J=8.0Hz,1H),4.72–4.57(m,2H),3.14(dd,J=14.2,6.0Hz,1H),2.99(dd,J= 14.2,7.4Hz,1H),1.75–1.55(m,3H),0.94(t,J=5.5Hz,6H)。
13 C NMR(101MHz,CDCl 3 )δ198.48,172.51,166.03,142.15,134.45,130.87,130.79, 130.06,128.93,127.93,119.75,115.70,115.49,59.78,51.67,40.78,34.13,24.84,22.85,22.22。
Example 55: preparation of Compounds 4-55
The preparation was identical to compound 4-1 (820 mg, 76.0% yield).
1 H NMR(400MHz,CDCl 3 )δ9.41(s,1H),7.56(d,J=15.4Hz,1H),7.46(s,2H),7.34(s, 3H),7.23(d,J=20.4Hz,9H),7.02(s,3H),6.72(s,1H),6.42(d,J=15.6Hz,1H),4.95(s,1H), 4.51(s,1H),3.15–2.86(m,4H)。
13 C NMR(101MHz,CDCl 3 )δ198.56,171.39,165.82,141.98,136.32,135.56,134.50, 130.00,129.37,129.23,128.90,128.76,127.95,127.16,127.09,119.88,59.78,54.47,38.46, 34.95。
Example 56: preparation of Compounds 4-56
The preparation was identical to compound 4-1 (660 mg, 62.0% yield).
1 H NMR(400MHz,CDCl 3 )δ9.63(d,J=10.5Hz,1H),7.62(d,J=14.8Hz,1H),7.49(s, 2H),7.35(s,3H),7.28–7.13(m,5H),6.92(s,1H),6.47(d,J=13.9Hz,2H),4.70(d,J=5.6Hz, 1H),4.53(s,1H),3.12(d,J=6.5Hz,2H),1.56(s,1H),1.22(d,J=29.4Hz,2H),0.94(dd,J= 16.1,6.6Hz,6H)。
13 C NMR(101MHz,CDCl 3 )δ198.31,167.68,159.72,134.65,129.90,129.27,128.82, 127.89,127.16,120.21,59.69,57.67,37.36,35.33,24.69,15.35,11.00。
Example 57: preparation of Compounds 4-57
The preparation was identical to compound 4-1 (740 mg, 77.0% yield).
1 H NMR(400MHz,CDCl 3 )δ9.61(s,1H),7.66(d,J=7.5Hz,1H),7.58(dd,J=15.1,8.3Hz, 1H),7.47(dd,J=9.0,6.8Hz,2H),7.30(dd,J=10.4,5.0Hz,3H),7.24–7.03(m,6H),6.71(d,J= 9.5Hz,1H),6.58–6.50(m,1H),4.71(ddd,J=20.8,16.3,9.1Hz,2H),3.09(dd,J=14.1,6.6Hz, 1H),3.04–2.93(m,1H),1.07(s,9H)。
13 C NMR(101MHz,CDCl 3 )δ198.76,171.05,165.76,141.65,135.84,134.61,129.85, 129.20,128.86,128.82,128.69,127.91,127.00,120.53,60.39,59.76,35.27,34.91,26.69。
Example 58: preparation of Compounds 4-58
The preparation was identical to compound 4-1 (350 mg, 72.0% yield).
1 H NMR(400MHz,CDCl 3 )δ9.62(s,1H),7.59(dd,J=15.6,5.1Hz,1H),7.48(dd,J=6.6, 2.6Hz,2H),7.36–7.30(m,4H),7.17(ddd,J=12.3,10.4,7.1Hz,5H),6.71(d,J=8.1Hz,1H), 6.51–6.44(m,1H),4.72–4.62(m,2H),3.15(dd,J=14.1,6.3Hz,1H),3.10–3.00(m,1H),0.97 (t,J=7.4Hz,3H),0.92–0.84(m,4H)。
13 C NMR(101MHz,CDCl 3 )δ198.68,172.18,165.95,141.75,135.71,134.62,129.90, 129.25,128.88,128.76,127.91,127.07,120.16,59.85,54.28,35.02,31.95,29.72,29.68,29.38, 25.89,22.71,14.14,9.93。
Example 59: preparation of Compounds 4-59
The preparation was identical to compound 4-1 (260 mg, 60.0% yield).
1 H NMR(400MHz,CDCl 3 )δ9.60(s,1H),7.62(d,J=15.5Hz,1H),7.48(s,2H),7.35(s, 3H),7.28–7.16(m,6H),7.05(s,1H),6.50(d,J=14.5Hz,1H),4.67(s,1H),4.03(t,J=38.2Hz, 3H),3.06(t,J=32.6Hz,2H)。
13 C NMR(101MHz,CDCl 3 )δ198.70,169.71,166.69,141.98,135.66,134.55,129.99, 129.24,128.89,128.81,127.96,127.15,119.75,59.94,43.39,34.91。
Example 60: preparation of Compounds 4-60
The preparation method was the same as for compound 4-1 (230 mg, 45.0% yield).
1 H NMR(400MHz,CDCl 3 )δ9.52(s,1H),7.57(d,J=15.7Hz,1H),7.48(s,2H),7.37(s, 3H),7.25–7.15(m,5H),7.10–6.98(m,4H),6.84(d,J=6.0Hz,1H),6.36(dd,J=15.5,6.2Hz, 2H),4.86(dd,J=14.4,7.2Hz,1H),4.62(q,J=6.6Hz,1H),3.18(d,J=6.9Hz,2H),3.14–3.06 (m,1H),3.02(dd,J=13.8,7.2Hz,1H)。
13 C NMR(101MHz,CDCl 3 )δ198.47,170.88,165.94,142.17,135.42,134.47,131.69, 130.04,129.26,128.91,128.80,127.95,127.13,124.48,119.62,115.34,59.77,53.66,35.07, 31.27。
Example 61: preparation of Compounds 4-61
The preparation method was the same as for compound 4-1 (600 mg, 75.0% yield).
1 H NMR(400MHz,CDCl 3 )δ9.61(s,1H),7.59(d,J=15.6Hz,1H),7.50–7.45(m,2H), 7.42(d,J=7.2Hz,1H),7.36–7.28(m,3H),7.24–7.18(m,2H),7.14(dd,J=10.4,7.7Hz,3H), 6.80(d,J=8.0Hz,1H),6.53–6.44(m,1H),4.74(dd,J=14.4,7.5Hz,1H),4.62(q,J=7.1Hz, 1H),3.15(dd,J=14.1,6.3Hz,1H),3.04(dd,J=14.1,7.4Hz,1H),1.93–1.79(m,1H),1.77– 1.63(m,1H),1.47–1.34(m,2H),0.99–0.87(m,3H)。
13 C NMR(101MHz,CDCl 3 )δ198.73,172.44,165.93,141.72,135.80,134.61,129.89, 129.25,128.88,128.73,127.90,127.03,120.19,59.89,53.01,34.98,34.77,18.87,13.86。
Example 62: preparation of Compounds 4-62
The preparation method was the same as for compound 4-1 (400 mg, 75.0% yield).
1 H NMR(400MHz,CDCl 3 )δ9.62(d,J=8.2Hz,1H),7.60(d,J=15.6Hz,1H),7.53–7.45 (m,2H),7.39–7.32(m,3H),7.27–7.12(m,6H),6.51(d,J=7.5Hz,1H),6.43(dd,J=15.6,8.1 Hz,1H),4.78–4.60(m,2H),3.23–3.13(m,1H),3.06(dd,J=14.1,7.4Hz,1H),1.40(dd,J= 30.9,6.9Hz,3H)。
13 C NMR(101MHz,CDCl 3 )δ198.69,172.69,165.81,141.94,135.67,134.56,129.98, 129.26,128.91,128.76,127.91,127.08,119.91,59.88,48.75,34.94,18.24。
Example 63: preparation of Compounds 4-63
The preparation method was the same as for compound 4-1 (420 mg, 65.0% yield).
1 H NMR(400MHz,CDCl 3 )δ9.64–9.55(m,1H),7.61(d,J=15.6Hz,1H),7.49(dd,J=6.5, 2.9Hz,2H),7.37–7.33(m,3H),7.25(d,J=5.2Hz,1H),7.22(d,J=7.5Hz,2H),7.20–7.09(m, 4H),6.42(dt,J=8.0,6.9Hz,2H),4.69(dd,J=14.7,8.5Hz,1H),4.61(dd,J=13.7,7.0Hz,1H), 3.20–3.11(m,1H),3.05(dd,J=14.1,7.3Hz,1H),1.87–1.49(m,10H),0.91(ddd,J=20.5,18.6, 10.5Hz,3H)。
13 C NMR(101MHz,CDCl 3 )δ198.72,165.98,141.92,135.71,129.95,129.29,128.90, 128.75,127.92,127.05,119.96,59.84,51.02,39.49,35.02,34.12,33.55,32.83,26.34,26.13, 26.00。
Example 64: preparation of Compounds 4-64
The preparation method was the same as for compound 4-1 (250 mg, 42.0% yield).
1 H NMR(400MHz,DMSO-d6)δ9.55–9.38(m,1H),8.65(dd,J=12.1,7.4Hz,1H),8.40 (dd,J=15.2,8.5Hz,1H),7.55(d,J=6.9Hz,2H),7.45–7.35(m,4H),7.26(s,4H),7.19(dd,J= 13.6,6.9Hz,3H),7.15–7.07(m,2H),7.05–6.97(m,2H),6.69(dd,J=15.8,10.3Hz,1H),4.74 (td,J=9.3,4.9Hz,1H),4.36(dddd,J=21.0,9.1,7.5,4.7Hz,1H),3.24–3.11(m,1H),3.08– 2.97(m,1H),2.90–2.67(m,2H)。
13 C NMR(101MHz,DMSO-d6)δ200.64,172.05,165.24,139.63,137.99,135.26,130.36, 130.01,129.78,129.68,129.42,128.72,128.02,126.80,125.79,122.19,60.21,54.09,37.98, 33.81。
Example 65: preparation of Compounds 4-65
The preparation method was the same as for compound 4-1 (220 mg, 40.0% yield).
1 H NMR(400MHz,DMSO-d6)δ9.47(dd,J=36.7,18.8Hz,1H),8.74–8.54(m,1H),8.40 (dd,J=18.3,8.0Hz,1H),7.56(dd,J=18.0,6.9Hz,2H),7.47–7.33(m,4H),7.33–7.15(m,7H), 7.13–7.04(m,2H),6.69(dd,J=18.7,16.1Hz,1H),4.69(s,1H),4.32(s,1H),3.16(t,J=14.1Hz, 1H),3.01(t,J=13.5Hz,1H),2.85(d,J=20.7Hz,2H)。
13 C NMR(101MHz,DMSO-d6)δ200.67,172.13,165.28,139.64,131.46,131.39,130.03, 129.66,129.42,128.71,128.01,126.80,115.38,115.17,60.18,54.39,33.77。
Example 66: preparation of Compounds 4-66
The preparation method was the same as for compound 4-1 (200 mg, yield 30.0%).
1 H NMR(400MHz,CDCl 3 )δ9.63(t,J=10.2Hz,1H),7.94(s,1H),7.72(dd,J=15.4,4.0 Hz,1H),7.47(dt,J=26.4,14.1Hz,6H),7.24–7.09(m,5H),6.74–6.56(m,1H),4.78(d,J=4.5 Hz,1H),4.72–4.61(m,1H),3.60–3.49(m,2H),3.28–3.15(m,1H),3.01–2.86(m,1H),2.46 (d,J=4.3Hz,1H),1.98(s,2H),1.86–1.75(m,1H)。
13 C NMR(101MHz,CDCl 3 )δ199.49,143.59,130.14,129.34,128.98,128.49,128.04, 126.75,117.55,59.68,47.30,34.99,26.57。
Example 67: preparation of Compounds 4-67
Methyl phosphonoacetate diethyl ester (57 ul,0.30 mmol) was dissolved in an appropriate amount of anhydrous tetrahydrofuran and charged with argon. Dropwise adding into tetrahydrofuran solution of sodium bis (trimethylsilyl) amide at-78deg.C, and stirring for 30min. Then, aldehyde (100 mg, 0.25 mmol) was dissolved in tetrahydrofuran and added dropwise to the above reaction solution, followed by stirring for 2 hours. After the reaction was completed, the reaction was quenched by addition of 1M hydrochloric acid solution. The solvent was removed by rotary evaporation under reduced pressure, dissolved in an appropriate amount of dichloromethane, washed successively with water, saturated citric acid, saturated sodium bicarbonate and saturated brine, and the organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was rotary-dried to give a crude product. The crude product was separated by column chromatography on silica gel to give a white solid (80 mg, 78%).
1 H NMR(400MHz,CDCl 3 )δ7.61(d,J=15.6Hz,1H),7.49(dd,J=6.6,2.9Hz,2H),7.39– 7.33(m,3H),7.20–7.15(m,2H),7.12(dd,J=12.8,7.8Hz,3H),7.05(d,J=8.5Hz,1H),6.94 (dd,J=15.7,5.2Hz,1H),6.39(dd,J=15.6,6.2Hz,1H),6.33(d,J=8.4Hz,1H),5.95–5.85(m, 1H),5.01–4.82(m,1H),4.70–4.55(m,1H),3.71(d,J=3.3Hz,3H),2.93–2.75(m,2H),1.74– 1.51(m,3H),0.93(dt,J=13.0,6.5Hz,6H)。
13 C NMR(101MHz,CDCl 3 )δ171.64,166.54,166.06,147.06,141.88,136.30,134.56, 129.98,129.33,128.92,128.54,127.90,126.76,121.02,120.05,51.83,51.69,51.15,40.66,40.52, 24.84,22.89,22.32。
Example 68: preparation of Compounds 4-68
Aldehyde (100 mg,0.25 mmol) was dissolved in acetonitrile, diethyl cyanomethylphosphonate (50 uL,0.30 mmol), lithium chloride (13 mg,0.30 mmol) and DBU (58 uL,0.38 mmol) were added in this order and stirred at room temperature for 2h. After the reaction was completed, a saturated ammonium chloride solution was added to quench. The solvent was removed by rotary evaporation under reduced pressure, dissolved in an appropriate amount of dichloromethane, washed successively with water, saturated citric acid, saturated sodium bicarbonate and saturated brine, and the organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was rotary-dried to give a crude product. The crude product was separated by column chromatography on silica gel to give a white solid (60 mg, 59%).
1 H NMR(400MHz,CDCl 3 )δ7.61(dd,J=9.9,5.7Hz,1H),7.51–7.45(m,2H),7.39–7.33 (m,3H),7.18(dt,J=23.4,7.4Hz,5H),7.09(d,J=7.0Hz,1H),6.66(dd,J=16.4,5.2Hz,1H), 6.41–6.29(m,2H),4.91–4.73(m,1H),4.69–4.50(m,1H),3.64–3.47(m,1H),3.07(dd,J= 17.2,9.7Hz,1H),1.76–1.56(m,3H),0.96–0.87(m,6H)。
13 C NMR(101MHz,CDCl 3 )δ171.89,166.51,166.36,153.28,142.27,137.46,134.38, 130.18,129.19,128.99,128.94,128.76,128.68,127.94,127.12,119.68,110.67,100.41,51.88, 41.81,40.03,24.87,22.86,22.18,16.64。
Example 69: preparation of Compounds 4-69
Aldehyde (100 mg,0.25 mmol) was dissolved in 50.0mL anhydrous tetrahydrofuran solution. The system was placed under argon and ethyl magnesium bromide (1.25 mL,1M,1.25 mmol) was added dropwise at-20deg.C using a constant pressure dropping funnel. After the addition, the reaction system was stirred at-20℃for 4h. After the reaction was completed, the solvent was distilled off under reduced pressure to obtain a crude product. The crude product was oxidized by Dess-Martin to give compounds 4-69 (70 mg, 68%).
1 H NMR(400MHz,CDCl 3 )δ7.64(dd,J=15.6,6.8Hz,1H),7.51–7.42(m,2H),7.35–7.31 (m,3H),7.24–7.18(m,2H),7.18–7.14(m,1H),7.13–7.07(m,3H),6.49(d,J=8.3Hz,1H), 6.44(d,J=15.6Hz,1H),4.85–4.75(m,1H),4.68(td,J=8.5,5.6Hz,1H),3.12–3.03(m,1H), 2.99–2.92(m,1H),2.48–2.28(m,2H),1.67(tt,J=12.8,6.3Hz,2H),1.58(dd,J=8.7,7.5Hz, 1H),1.00(t,J=7.2Hz,3H),0.92(t,J=7.6Hz,6H)。
13 C NMR(101MHz,CDCl 3 )δ209.03,172.04,165.83,141.73,136.02,134.68,129.84, 129.21,128.85,128.65,127.89,126.99,120.16,58.94,51.74,41.30,37.60,34.21,24.85,22.90, 22.24,7.34。
Example 70: preparation of Compounds 4-70
The preparation was identical to that of compounds 4-69 (70 mg, 68%).
1 H NMR(400MHz,CDCl 3 )δ7.63(dd,J=15.6,7.3Hz,1H),7.48(dd,J=6.5,2.8Hz,2H), 7.36–7.29(m,3H),7.23–7.11(m,4H),7.08(d,J=6.9Hz,2H),6.56(d,J=8.4Hz,1H),6.51–6.32(m,3H),5.84(dd,J=9.8,1.7Hz,1H),5.20–5.08(m,1H),4.71(td,J=8.4,5.7Hz,1H),3.15 (dd,J=13.9,6.3Hz,1H),3.04–2.93(m,1H),1.73–1.55(m,3H),0.96–0.88(m,6H)。
13 C NMR(101MHz,CDCl 3 )δ197.11,172.01,165.75,141.64,135.67,134.74,133.33, 130.45,129.79,129.47,128.84,128.51,127.89,126.96,120.28,57.14,51.79,41.49,37.55,24.85, 22.88,22.27。
Example 71: inhibitor in vitro cytotoxicity (CC) 50 ) Experiment
RD cells were seeded in 96-well plates at 37℃in 5% CO 2 Incubate in incubator for 24 hours. The inhibitor to be tested was diluted into working solutions of 100. Mu.M, 33.33. Mu.M, 11.11. Mu.M, 3.70. Mu.M, 1.23. Mu.M, 0.41. Mu.M, 0.14. Mu.M, 0.046. Mu.M and 0.015. Mu.M, respectively. The cell supernatant in the 96-well plate was aspirated, 100. Mu.L of inhibitor working solution at different concentrations was added to each well, each concentration was repeated 3 times, and a cell control group was set at 37℃with 5% CO 2 Culturing for 24 hours. The cytotoxicity of the inhibitors was detected with WST-1 cell proliferation and cytotoxicity detection kit (Roche), 10. Mu.L of WST-1 was added to each well for staining of living cells, and after 1 hour, fluorescence was read at 490nM in an ELISA reader, and the data was analyzed using GraphPad Prism 7.0. The results are shown in the following table.
Example 72: inhibitor of in vitro cell Activity (EC) 50 ) Experiment
For the inhibition evaluation of the cell activity of SARS-CoV-2, the P3 laboratory of the Chinese institute of Karaoke virus was used to infect cells with SARS-CoV-2 virus (GISAID access No. EPI_ISL_ 402124) according to a certain MOI, then different compounds to be tested were added to the cells, and the compounds which could inhibit the virus amplification were primarily screened out by observing the cytopathic condition. The inhibition effect of the drug on the virus is further clarified by detecting the cytotoxicity of the candidate drug, the influence of the drug on the virus titer and the like, and the EC of the drug to the virus is determined 50 (half effective concentration) the inhibitory effect of the drug on the virus was evaluated. ResultsThe following table.
/>
/>
/>
/>
The embodiments of the present invention have been described above. However, the present invention is not limited to the above embodiment. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims (9)
1. A compound of formula I:
wherein:
R 1 represents Z-Y-X-,
x represents a bond; alternatively, O;
y represents a bond; alternatively, C 1-10 Straight-chain or branched alkylene, C 2-10 Straight-chain or branched alkenylene or C 2-10 A linear or branched alkynylene group, the alkylene, alkenylene, or alkynylene group being unsubstituted or substituted with 1 or more halogens;
z represents H; c (C) 3-10 Cycloalkyl or 3-10 membered heterocycloalkyl containing 1-3 heteroatoms independently selected from N, O, S, said cycloalkyl or heterocycloalkyl being unsubstituted or substituted with 1 or more substituents independently selected from halogen, C 1-10 Straight-chain or branched alkyl, C 2-10 Straight-chain or branched alkenyl, C 2-10 Straight or branched alkynyl, C 1-10 Linear or branched alkyl oxy, hydroxy, amino, cyano, nitro, trifluoromethyl, trifluoromethoxy groups; alternatively, C 6-10 Aryl or 5-10 membered heteroaryl containing 1-3 heteroatoms independently selected from N, O, S, said aryl or heteroaryl being unsubstituted or substituted with 1 or more substituents independently selected from halogen, C 1-10 Straight-chain or branched alkyl, C 2-10 Straight-chain or branched alkenyl, C 2-10 Straight or branched alkynyl, C 1-10 Straight-chain or branched alkyl oxy, unsubstituted or substituted by C 1-6 Alkyl-substituted phenyl, hydroxy, amino, cyano, nitro, trifluoromethyl, trifluoromethoxy groups;
provided that when Y is a bond, Z is not H;
R 2 represents phenyl, C 1-10 Straight-chain or branched alkylene phenyl, C 2-10 Straight-chain or branched alkenylene phenyl or C 2-10 Straight or branched alkynylene phenyl, said phenyl being unsubstituted or substituted with 1 or more groups independently selected from halogen, C 1-10 Straight-chain or branched alkyl, C 2-10 Straight-chain or branched alkenyl, C 2-10 Straight or branched alkynyl, C 1-10 Linear or branched alkyl oxy, hydroxy, amino, cyano, nitro, trifluoromethyl, trifluoromethoxy groups;
R 3 represents hydrogen; c (C) 1-10 Straight-chain or branched alkyl, C 2-10 Straight-chain or branched alkenyl or C 2-10 A linear or branched alkynyl group, said alkyl, alkenyl or alkynyl group being unsubstituted or substituted with 1 or more halogens; c (C) 3-10 Cycloalkyl, C 1-10 Straight-chain or branched alkylene C 3-10 Cycloalkyl, C 2-10 Straight-chain or branched alkenylene C 3-10 Cycloalkyl, C 2-10 Straight-chain or branched alkynylene C 3-10 Cycloalkyl, phenyl, C 1-10 Straight-chain or branched alkylene phenyl, C 2-10 Straight-chain or branched alkenylene phenyl or C 2-10 A straight or branched alkynylene phenyl group, said cycloalkyl or phenyl group being unsubstituted or substituted with 1 or more groups independently selected from halogen, C 1-10 Straight-chain or branched alkyl, C 2-10 Straight-chain or branched alkenyl, C 2-10 Straight or branched alkynyl, C 1-10 Linear or branched alkyl oxy, hydroxy, amino, cyano, nitro, trifluoromethyl, trifluoromethoxy groups;
R 4 represents-CHO.
2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein:
R 1 represents Z-Y-X-,
x represents a bond; alternatively, O;
y represents a bond; alternatively, C 1-6 Straight-chain or branched alkylene, C 2-6 Straight-chain or branched alkenylene, or C 2-6 A linear or branched alkynylene group, said alkylene, alkenylene, or alkynylene group being unsubstituted or substituted with 1-3 fluorine groups;
z represents H; c (C) 3-10 Cycloalkyl or 3-10 membered heterocycloalkyl containing 1 heteroatom selected from N, O, S, said cycloalkyl or heterocycloalkyl being unsubstituted or substituted with 1-3 groups independently selected from halogen, C 1-6 Straight-chain or branched alkyl, C 2-6 Straight-chain or branched alkenyl, C 2-6 Straight or branched alkynyl, C 1-6 Linear or branched alkyl oxy, hydroxy, amino, cyano, nitro, trifluoromethyl, trifluoromethoxy groups; alternatively, C 6-10 Aryl or 5-10 membered heteroaryl containing 1-3 heteroatoms independently selected from N, O, S, said aryl or heteroaryl being unsubstituted or substituted with 1-3 heteroatoms independently selected from halogen, C 1-6 Straight-chain or branched alkyl, C 2-6 Straight-chain or branched alkenyl, C 2-6 Straight or branched alkynyl, C 1-6 Linear or branched alkyl oxygen, phenyl, hydroxy, amino, cyano, nitro, trifluoromethyl groups;
provided that when Y is a bond, Z is not H;
R 2 represents phenyl, C 1-6 Straight-chain or branched alkylene phenyl, C 2-6 Straight-chain or branched alkenylene phenyl or C 2-6 Straight or branched alkynylene phenyl groups, said phenyl groups being unsubstituted or substituted with 1 to 3 groups independently selected from halogen, C 1-6 Straight-chain or branched alkyl, C 2-6 Straight-chain or branched alkenyl, C 2-6 Straight or branched alkynyl, C 1-6 Linear or branched alkyl oxy, hydroxy, amino, cyano, nitro, trifluoromethyl, trifluoromethoxy groups;
R 3 represents hydrogen; methyl, n-propyl, C 4-6 Straight-chain or branched alkyl, C 4-6 Straight-chain or branched alkenyl or C 4-6 A linear or branched alkynyl group, said alkyl, alkenyl or alkynyl group being unsubstituted or substituted with 1 to 3 fluoro groups; c (C) 3-10 Cycloalkyl, C 1-6 Straight-chain or branched alkylene C 3-10 Cycloalkyl, C 2-6 Straight-chain or branched alkenylene C 3-10 Cycloalkyl, C 2-6 Straight-chain or branched alkynylene C 3-10 Cycloalkyl, phenyl, C 1-6 Straight-chain or branched alkylene phenyl, C 2-6 Straight-chain or branched alkenylene phenyl or C 2-6 Straight or branched alkynylene phenyl, said cycloalkyl or phenyl being unsubstituted or substituted with 1 to 3 groups independently selected from halogen, C 1-6 Straight-chain or branched alkyl, C 2-6 Straight-chain or branched alkenyl, C 2-6 Straight or branched alkynyl, C 1-6 Linear or branched alkyl oxy, hydroxy, amino, cyano, nitro, trifluoromethyl, trifluoromethoxy groups;
R 4 represents-CHO.
3. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein:
R 1 represents Z-Y-X-,
x represents a bond; alternatively, O;
y represents a bond; or, C1-3 straight or branched alkylene, C2-3 straight or branched alkenylene;
z represents H; a cyclohexenyl or 6 membered heterocycloalkyl containing 1 heteroatom selected from N, O, S, said cycloalkyl or heterocycloalkyl being unsubstituted or substituted with 1-3 groups independently selected from halo, methyl, methoxy, hydroxy, amino, cyano, nitro, trifluoromethyl, trifluoromethoxy; or, phenyl, naphthyl, pyrrolyl, furanyl, thienyl, indolyl, pyridinyl, isoxazolyl, pyrimidinyl, said substituents being unsubstituted or substituted with 1 to 3 groups independently selected from halogen, methyl, methoxy, phenyl, hydroxy, amino, cyano, nitro, trifluoromethyl, trifluoromethoxy;
provided that when Y is a bond, Z is not H;
R 2 represent C 1-3 A linear or branched alkylene phenyl group, said phenyl group being unsubstituted or substituted with 1 group selected from halogen, methyl, methoxy, hydroxy, amino, cyano, nitro, trifluoromethyl, trifluoromethoxy;
R 3 Represents hydrogen; methyl, n-propyl, C 4-6 Linear or branched alkyl; c (C) 1-3 Linear or branched alkylene cyclohexanyl or C 1-3 A linear or branched alkylene phenyl group, said cyclohexyl or phenyl group being unsubstituted or substituted with 1 group selected from halogen, methyl, methoxy, hydroxy, amino, cyano, nitro, trifluoromethyl, trifluoromethoxy;
R 4 represents-CHO.
4. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein:
R 1 represents Z-Y-X-,
x represents a bond; alternatively, O;
y represents a bond; alternatively, CH 2 、CH=CH;
Z represents a cyclohexenyl or a 6 membered heterocycloalkyl containing 1O atom, said cyclohexenyl or heterocycloalkyl being unsubstituted or substituted with 1 or 2 groups independently selected from halogen, methyl, methoxy, nitro; or, phenyl, naphthyl, pyrrolyl, furanyl, thienyl, indolyl, pyridyl, isoxazolyl, pyrimidinyl, said substituents being unsubstituted or substituted with 1 or 2 groups independently selected from halogen, methyl, vinyl, methoxy, phenyl, nitro;
R 2 represents a methylenephenyl or ethylenephenyl group, said phenyl group being unsubstituted or substituted in ortho, meta or para position with respect to the methylene or ethylene group by 1 group selected from halogen, methoxy, nitro, trifluoromethyl;
R 3 Represents methyl, n-propyl, n-butyl, isobutyl, sec-butyl, tert-butyl; a methylenecyclohexenyl or methylenephenyl group, said cyclohexenyl or phenyl group being unsubstituted or substituted with 1 group selected from halogen in the ortho, meta or para position to the methylene group;
R 4 represents-CHO.
5. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein:
R 1 selected from the group consisting of pentyl, phenyl, ethenylphenyl, methylenephenyl, -O-methylenephenyl, phenyleophenyl, naphthyl, pyrrolyl, furanyl, thienyl, indolyl, methyleneindolyl, pyridyl, isoxazolyl, cyclohexenyl, tetrahydropyran, said substituents being unsubstituted or substituted with 1 or 2 groups independently selected from fluoro, chloro, bromo, methyl, vinyl, methoxy, nitro;
R 2 selected from the group consisting of methylenephenyl, said phenyl being unsubstituted or substituted with 1 group selected from fluoro, chloro, bromo, methoxy, nitro, trifluoromethyl, ortho, meta or para to the methylene;
R 3 selected from isobutyl; a methylenecyclohexenyl or methylenephenyl group, said cyclohexenyl or phenyl group being unsubstituted or substituted with 1 fluorine at the ortho, meta or para position relative to the methylene group;
R 4 represents-CHO.
6. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound of formula I is selected from:
。
7. a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula I as defined in any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
Preferably, the pharmaceutical composition further comprises other compounds for treating diseases caused by SARS-CoV-2 infection.
Preferably, the other compound for treating a disease caused by SARS-CoV-2 infection is selected from antiviral agents such as acyclovir, adefovir, monabivalir and the like, antiinfectives, immunomodulators such as alpha, beta, delta-interferon and the like, primary protease inhibitors, S protease inhibitors, M protein inhibitors, and/or antibiotics and the like.
8. Use of a compound of formula I as defined in any one of claims 1 to 6 or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the prophylaxis and/or treatment of a disease caused by SARS-CoV-2 infection in a mammal.
Preferably, the mammal is a human.
Preferably, the disease caused by SARS-CoV-2 infection is a novel coronavirus pneumonia.
9. Use of a compound of formula I as defined in any one of claims 1 to 6 or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the prophylaxis and/or treatment of a disease caused by SARS-CoV-2 infection in a mammal in combination with other compounds for the treatment of a disease caused by SARS-CoV-2 infection.
Preferably, the mammal is a human.
Preferably, the disease caused by SARS-CoV-2 infection is a novel coronavirus pneumonia.
Preferably, the other compound for treating a disease caused by SARS-CoV-2 infection is selected from antiviral agents such as acyclovir, adefovir, monabivalir and the like, antiinfectives, immunomodulators such as alpha, beta, delta-interferon and the like, primary protease inhibitors, S protease inhibitors, M protein inhibitors, and/or antibiotics and the like.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210072991.9A CN116514678A (en) | 2022-01-21 | 2022-01-21 | Novel coronavirus inhibitor, pharmaceutical composition containing same and use thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210072991.9A CN116514678A (en) | 2022-01-21 | 2022-01-21 | Novel coronavirus inhibitor, pharmaceutical composition containing same and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116514678A true CN116514678A (en) | 2023-08-01 |
Family
ID=87403414
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210072991.9A Pending CN116514678A (en) | 2022-01-21 | 2022-01-21 | Novel coronavirus inhibitor, pharmaceutical composition containing same and use thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116514678A (en) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103145608A (en) * | 2011-12-07 | 2013-06-12 | 南开大学 | Anti-enterovirus 71 (EV71) caprolactam compounds, and preparation method and application thereof |
CN108025001A (en) * | 2015-07-24 | 2018-05-11 | 安可初克公司 | For treating the gamma secretase modulators of immune system dysfunction |
CN110105348A (en) * | 2019-03-08 | 2019-08-09 | 南开大学 | The preparation and purposes of novel michael acceptor class enteric virus71 type inhibitor |
CN113143918A (en) * | 2020-04-24 | 2021-07-23 | 中国科学院微生物研究所 | Application of boceprednol in treating or improving novel coronavirus pneumonia |
CN113801187A (en) * | 2020-06-12 | 2021-12-17 | 南开大学 | Preparation and application of Michael acceptor type main protease inhibitor targeting novel coronavirus |
-
2022
- 2022-01-21 CN CN202210072991.9A patent/CN116514678A/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103145608A (en) * | 2011-12-07 | 2013-06-12 | 南开大学 | Anti-enterovirus 71 (EV71) caprolactam compounds, and preparation method and application thereof |
CN108025001A (en) * | 2015-07-24 | 2018-05-11 | 安可初克公司 | For treating the gamma secretase modulators of immune system dysfunction |
CN110105348A (en) * | 2019-03-08 | 2019-08-09 | 南开大学 | The preparation and purposes of novel michael acceptor class enteric virus71 type inhibitor |
CN113143918A (en) * | 2020-04-24 | 2021-07-23 | 中国科学院微生物研究所 | Application of boceprednol in treating or improving novel coronavirus pneumonia |
CN113801187A (en) * | 2020-06-12 | 2021-12-17 | 南开大学 | Preparation and application of Michael acceptor type main protease inhibitor targeting novel coronavirus |
Non-Patent Citations (2)
Title |
---|
MADHUSUDAN VERMA ET, AL.: ""Novel Potential Inhibitors Against SARS-CoV-2 Using Artificial Intelligence"", 《CHENRXIV》, 2 September 2020 (2020-09-02), pages 1 - 12 * |
ZHU, LILI ET, AL.: ""Peptide aldehyde inhibitors challenge the substrate specificity of the SARS-coronavirus main protease"", 《ANTIVIRAL RESEARCH》, 11 August 2011 (2011-08-11), pages 204 - 212, XP028325599, DOI: 10.1016/j.antiviral.2011.08.001 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10150740B2 (en) | 6,7-dihydropyrido[2,1-A]phthalazin-2-ones for the treatment and prophylaxis of hepatitis B virus infection | |
EP3325477B1 (en) | Novel tricyclic 4-pyridone-3-carboxylic acid derivatives for the treatment and prophylaxis of hepatitis b virus infection | |
US10968217B2 (en) | Tetrahydropyridopyrimidines for the treatment and prophylaxis of hepatitis B virus infection | |
ES2969868T3 (en) | Selective P2X3 antagonists for use in the treatment of chronic cough without loss of taste response | |
JP2024503755A (en) | Nucleoside compounds for the treatment of viral infections and their uses | |
US10023554B2 (en) | Halogen-substituted heterocyclic compound salt | |
CA2855204A1 (en) | Benzimidazoles for the treatment and prevention of respiratory syncytial virus infection | |
CN116514678A (en) | Novel coronavirus inhibitor, pharmaceutical composition containing same and use thereof | |
US12083092B2 (en) | Antiviral 1,3-di-oxo-indene compounds | |
CN113801187A (en) | Preparation and application of Michael acceptor type main protease inhibitor targeting novel coronavirus | |
JP5938537B1 (en) | Prodrug | |
CN117069685B (en) | Cinnamoyl alkyl polyketone compound, preparation method and application thereof | |
WO2024098856A1 (en) | Anti-influenza-virus derivatives and use thereof | |
CN113004250B (en) | Process for preparing substituted triazole derivatives | |
US20240083884A1 (en) | Compounds and method for preparing the same | |
US20230365535A1 (en) | Compounds and method for preparing the same | |
JP5408660B2 (en) | Paraterphenyl compound, pharmacologically acceptable salt thereof, production method and use thereof | |
CN116438176A (en) | 2-phenylbenzotriazol-5-amine derivatives for the treatment and prevention of Hepatitis B Virus (HBV) infection | |
CN113402414A (en) | Benzoic acid derivative and preparation method and pharmaceutical application thereof | |
AU2521501A (en) | 2-arylquinoline derivatives, preparation and therapeutic use thereof | |
JP2000355584A (en) | Production of 2-phenyl-3-aminopyridine, phenyl- substituted derivative of the compound and salt of the compound |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |